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Preface 
 
Technetium-99m (99mTc) is the principal radioisotope used in medical 
diagnostics worldwide. Current estimates are that 99mTc is used in 30 million 
procedures per year globally and accounts for 80 to 85% of all diagnostic 
investigations using Nuclear Medicine techniques. Its 6-hour physical half-life 
and the 140 keV photopeak makes it ideally suited to medical imaging using 
conventional gamma cameras. 99mTc is derived from its parent element 
molybdenum-99 (99Mo) that has a physical half-life of 66 hours. At present 99Mo 
is derived almost exclusively from the fission of uranium-235 targets (using 
primarily highly-enriched uranium) irradiated in a small number of research 
nuclear reactors.  
 
A global shortage of 99Mo in 2008/09 exposed vulnerabilities in the supply chain 
of medical radioisotopes. In response, and at the request of member states, the 
Organization of Economic Co-operation and Development (OECD) Nuclear 
Energy Agency (NEA) assembled a response team and in April 2009 formed a 
High-Level Group on the security of supply of Medical Radioisotopes (HLG-MR). 
The HLG-MR terms of reference are: to review the total 99Mo supply chain from 
uranium procurement for targets to patient delivery; to identify weak points and 
issues in the supply chain in the short, medium and long-term; to recommend 
options to address vulnerabilities to help ensure stable and secure supply of 
radioisotopes. 
  
The UK has no research nuclear reactors and relies on the importation of 99Mo 
and other medical radioisotopes (e.g. Iodine-131) from overseas (excluding PET 
radioisotopes). The UK is therefore vulnerable not only to global shortages, but 
to problems with shipping and importation of the products. In this context 
Professor Erika Denton UK national Clinical Director for Diagnostics requested 
that the British Nuclear Medicine Society lead a working group with 
stakeholders including representatives from the Science & Technology Facilities 
Council (STFC) to prepare a report. The group had a first meeting on 10 April 
2013 followed by a working group meeting with presentations on 9th September 
2013 where the scope of the work required to produce a report was agreed. 
 
The objectives of the report are: to describe the status of the use of medical 
radioisotopes in the UK; to anticipate the potential impact of shortages for the 
UK; to assess potential alternative avenues of medical radioisotope production 
for the UK market; and to explore ways of mitigating the impact of medical 
radioisotopes on patient care pathways. The report incorporates details of a visit 
to the Cyclotron Facilities at Edmonton, Alberta and at TRIUMF, Vancouver BC in 
Canada by members of the report team. 
 
Brian Neilly, December 2014.  
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Glossary of Terms 
 
AECL Atomic Energy Canada Ltd. 
ANSTO Australian Nuclear Science & Technology Organization. 
ARSAC Administration of Radioactive Substances Advisory 
Committee. 
Becquerel (Bq) The international (SI) unit to measure radioactivity. One 
Becquerel is equal to one nuclear decay per second. 
Activity is typically expressed as mega (106, MBq), giga 
(109, GBq) or terabecquerel (1012, TBq) units of 
radioactivity. 
BNMS British Nuclear Medicine Society. 
BP British Pharmacopoeia. 
BR-2 Belgian Reactor 2. 
CT Computed Tomography, a technique that uses a 
computer to generate multiple X-ray images in three 
orthogonal planes. 
Curie (Ci) A unit to measure radioactivity. One Curie is 3.7 x 1010 
Becquerel (37 GBq). Often expressed in millicuries where 
1 mCi is 1/1000 of a Ci. 
Cyclotron A particle accelerator that uses electromagnetic fields to 
accelerate a charge towards a target to produce 
radionuclides, commonly 18F for PET imaging. 
Electron volt (eV) A unit of energy equal to approximately 1.6×10
−19
 joules, 
typically expressed as kilo (10
3
, keV) or mega (10
6
, MeV) 
electron volts. 
18 FDG 18F-Fluorodeoxyglucose, the principal 
radiopharmaceutical used in PET imaging. 
FCR Full Cost Recovery, term used to describe the objective to 
ensure that all of the costs associated with irradiation 
(operational and capital costs) are recovered. 
Gamma Camera Equipment used to image gamma radiation emitted from 
a patient previously administered with a 
radiopharmaceutical. 
Generator A mechanism that permits elution of short-lived 
radionuclides from longer-lived precursors e.g. 
99Mo/99mTc and 81Rb/81mKr. 
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GMC General Medical Council. 
GMP Good Manufacturing Practice. 
HEU Highly enriched uranium containing more than 20% 
235Uranium. 
HFR High Flux Reactor, Petten, Netherlands. 
HLG-MR High Level Group-Medical Radioisotopes, the NEA-OECD 
group set up to oversee the global response to the 
molybdenum shortages. 
Jules Horowitz New French Nuclear Reactor to replace OSIRIS. 
LEU Low enriched uranium (≤ 20%). 
Linac A linear particle accelerator is a type of particle 
accelerator commonly used in radiotherapy to accelerate 
electrons into a target to produce a beam of high energy 
X-rays.  
MDT Multidisciplinary Team Meeting. 
MHRA Medicine and Healthcare Products Regulatory Agency. 
MRI Magnetic Resonance Imaging, an imaging technique that 
uses magnetic and radiofrequency fields to reconstruct 
high-resolution images of the body. 
MRT Molecular Radiotherapy, the branch of nuclear medicine 
that uses the properties of radionuclides to treat disease. 
MSC Modernising Scientific Careers. 
99Mo Molybdenum-99, a radioisotope of Molybdenum and the 
precursor of 99mTc. 
MWth 106 Watts (thermal). 
NRU National Research Universal Reactor at Chalk River, 
Canada. 
NEA Nuclear Energy Authority. 
OECD Organisation for Economic Co-operation & Development. 
OPAL Open Pool Australia Light water reactor. 
ORC Outage Reserve Capacity, the system in place to ensure 
that processors hold sufficient product in reserve to 
allow for unplanned or extended shutdowns of reactors. 
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OSIRIS Experimental Nuclear Reactor at Saclay, France. 
PALLAS Research Nuclear Reactor at Petten to replace HFR. 
PET Positron Emission Tomography, a diagnostic imaging test 
based on the detection of radiation from positrons 
emitted from short-lived radioisotopes (e.g. 18F-FDG) 
injected into a patient. 
PET-CT Positron Emission Tomography with Computed 
Tomography. 
PET-MR Positron Emission Tomography with Magnetic 
Resonance Imaging. 
Ph. Eur. European Pharmacopeia. 
Radiopharmaceutical A pharmaceutical or a drug labelled with a radionuclide 
used in nuclear medicine imaging and therapy. 
Radiotherapeutics Term used to describe the use of beta or alpha-emitting 
radionuclides in therapy of disease especially cancer. 
RCP Royal College of Physicians. 
RCR Royal College of Radiologists. 
SAFARI-1 South African Nuclear Research Reactor. 
Sievert The international (SI) unit of effective radiation dose, 
commonly expressed in millisieverts (mSv, 10-3 Sievert). 
SCoR Society and College of Radiographers. 
SPECT Single Photon Emission Tomography, an imaging 
technique that uses images from a gamma camera to 
reconstruct a series of trans-axial slices that are 
combined to produce a three-dimensional dataset. 
SPECT-CT Single Photon Emission Tomography combined with 
Computed Tomography. 
STFC Science & Technology Facilities Council. 
STP Scientist Training Programme. 
99mTc Technetium 99m, the principal radioisotope used in 
medical imaging. 
US Ultrasound scan. 
USP US Pharmacopoeia. 
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Executive Summary 
 
Molybdenum: Global Supply Perspective 
 
 Technetium-99m (99mTc) is the daughter product of molybdenum-99 and is 
the principal radioisotope used for medical diagnostic imaging, accounting 
for almost 85% of the global radiopharmaceutical market estimated to be 
in excess of 3 billion USD. 
 99mTc is a versatile element that supports a spectrum of different 
radiopharmaceuticals targeting multiple disease sites, in particular bone, 
cardiac, renal, lung and endocrine disorders. Its relatively short physical 
half-life results in a low radiation dose burden for the patient.  
 At present approximately 600,000 imaging procedures using 99mTc are 
undertaken each year in the UK. The global estimate is around 40 million 
procedures per annum. 
 There is good evidence that the demand for 99mTc for imaging diagnostics 
will continue in the short to medium term. Growth predictions are difficult 
to assess but demand will continue to grow at a slowing rate (estimated at 
0.5% per annum until about 2030). Estimates are that 99mTc will be needed 
for at least the next 15-25 years. 
 As new technologies for molecular imaging (e.g. PET) develop, 99mTc’s 
share of the medical diagnostics market is expected to fall but in context of 
an increasing annual budget to over 4.1billion US dollars, the demand for 
99mTc will remain high. The future demand for 99mTc will be driven by the 
availability of new diagnostic ligands. 
 There are systematic problems in the global supply chain for medical 
radioisotopes. These problems are complex, rendering the supply system 
fragile and subject to unpredictable outages. 
 99Mo is at present produced exclusively in a small number of research 
nuclear reactors most of which are >40 years old. Of these reactors OSIRIS 
(France) and NRU (Canada) will cease production permanently at the end 
of 2015 and 2016 respectively. Loss of these reactors will remove 
approximately 30% of the global production of molybdenum-99 from the 
supply chain by the end of 2016. 
 The production of 99Mo until now has been achieved by nuclear reactor-
based fission of highly enriched (weapons-grade) uranium. For non-
proliferation reasons, 99Mo derived from HEU will no longer be accepted 
beyond 2020.  
 The economic model of medical radioisotope production is poorly 
developed and is a disincentive to investment and to the development of 
any outage reserve capacity (ORC).  
 The OECD NEA HLG-MR has determined that full cost recovery (FCR) and a 
mechanism for ORC is vital to sustain future global supply of 99Mo from 
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reactors. As a result of the implementation of FCR and ORC, it is inevitable 
that the cost of 99mTc will increase. The magnitude and timing of this 
increase in cost of 99mTc is uncertain.   
 Individual countries and companies are exploring options for a future 
supply of medical radioisotopes. The UK at present has limited capacity for 
the production of radioisotopes for medical use restricted to a small 
number of cyclotrons that manufacture mainly 18F- for PET imaging with 
FDG. 
 There are potential reactor-based and non-reactor solutions for the secure 
supply of 99Mo and 99mTc in the medium to long-term future however, there 
are many assumptions as to the availability of new reactor projects as 
outlined by the latest HLG-MR report (July 2014). 
 The purpose of the present report is to assess and forecast the UK’s 
requirement for medical radioisotopes and the options that are available 
for the development of secure and sustainable source and distribution of 
radioisotopes for medical use. 
Nuclear Medicine: UK perspective 
 
 Nuclear Medicine as currently practiced in the UK is a multidisciplinary 
specialty employing a workforce of more than 2,500 individuals 
 There has been a significant increase over time in the NHS of the availability 
of gamma cameras with SPECT and SPECT-CT capability. These cameras are 
optimal for imaging using 99mTc-based radiotracers. 
 The demand for conventional (non-PET) imaging and non-imaging 
diagnostics in the UK is in the region of 600,000 per annum. Bone, cardiac 
and renal investigations make up more than half of the requests for these 
investigations. 
 There is an increasing availability of PET-CT across the UK for a growing 
number of indications. In most of these centres there is limited capacity for 
further growth due to high use for FDG-PET-CT for oncological indications. 
Non-oncological and non-FDG PET indications presently make up only 10% 
of the total. 
 The cyclotrons available in the UK for the production of 18FDG and other 
PET-tracers are not suitable for the large-scale production of 99mTc. Higher-
energy cyclotrons would have to be installed if commercial quantities of 
99mTc are to be produced.  
 Nuclear medicine services in the UK receive generators from only three 
commercial companies. The majority of radiopharmacy services in the UK 
have been affected by generator shortages. 
 Most nuclear medicine services in the UK have developed contingencies to 
deal with periods of shortage. These include re-scheduling the patient, 
employing alternative radiopharmaceuticals, or using lower administered 
 14 
activities, none of which are optimal. In a small proportion of cases this 
change has affected future patient referrals. 
 There is evidence of unnecessary waste of radioactivity arising from the 
current generator delivery schedules to departments. Delivery and elution 
schedules for 99mTc generators are highly complex and software options 
exist to facilitate the correct choice. This could be improved through 
partnerships with the commercial generator suppliers. 
 
Alternative Imaging Strategies UK 
 
 The 2010 ARSAC report proposed 8 recommendations as to how to 
mitigate the impact of periods of 99mTc shortage. 
 The response of the nuclear medicine community to dose saving and to 
alternatives is maturing. 
 Most alternative radionuclides to 99mTc will be more expensive and some 
deliver much higher radiation doses to patients and staff.  
 Non-radionuclide alternatives are available in certain circumstances but 
may not achieve the same diagnostic accuracy, may not be useable in all 
patients and would displace work on other imaging machines such as CT 
and MR which themselves may be limited in capacity. 
 It is apparent that patients will be best served by having access to a 
plentiful supply of 99mTc for the most effective diagnostic tests. 
 Patients will be poorly-served by not having a cheap, plentiful supply of 
99mTc 
 The present distribution of Cyclotrons within the UK is patchy at and while 
most areas have ready access to FDG, those without Cyclotrons cannot take 
advantage of the use of the shorter-lived Cyclotron-manufactured 
radioisotopes  
Non-Reactor Production of 99mTc 
 
 Sourcing secure supplies of 99Mo or 99mTc from accelerator-based (linear 
accelerators, cyclotrons or other technologies) is an option that the UK 
should consider. 
 The model of cyclotron-based manufacture of 99mTc from 100Mo is one that 
is being developed and evaluated in Canada and the production of 
commercial quantities has been shown to be feasible. 
 When compared to other technical approaches, it is concluded that direct 
cyclotron production of 99mTc is most promising model for the UK; 
compared to other approaches, cyclotron production is thought to be the 
most mature and it also lends itself better to co-production with other 
radioisotopes such as 18F. 
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Cyclotron-Produced 99mTc 
 
 International efforts have demonstrated that production of 99mTc by 
cyclotron is a feasible technology, though it requires infrastructure and 
incurs ongoing costs of daily production and transport. The delegation to 
Canada established the following: 
 It has been demonstrated on a small scale that standard 99mTc based 
radiopharmaceuticals can be prepared using cyclotron-produced 99mTc and 
that their chemical and biological properties appear equivalent. 
 Two production methodologies with the potential to supplement UK 99mTc 
supplies on a commercial basis have been identified.  
 The production 99mTc on high-powered cyclotrons has been accomplished 
with the potential for routine production of TBq amounts of radioactivity. 
 99mTc cyclotron production requires high-energy cyclotrons and cannot be 
achieved using the existing medical cyclotron facilities in the UK currently 
used for the production of positron-emitting radiopharmaceuticals.  
 The key innovation and intellectual property concerning cyclotron 
production of 99mTc rests with the beam targetry and target plate 
technology. 
 Efficient methods for the radiochemical separation and recovery of 
Na99mTcO4 from 100Mo targets have been developed. 
 The radionuclidic purity of cyclotron-produced 99mTc is well understood. 
Small amounts of 93Tc, 94mTc, 94Tc, 95Tc, and 96Tc impurities may be present 
in variable amounts and with optimisation of cyclotron energy these 
radionuclidic contaminants may contribute an additional 10% in effective 
radiation dose to the patient. 
 Initial work on radiolabelling standard kit formulations has been carried 
out and products have met the current quality control specifications.   
 The position relating to the regulatory approval of cyclotron produced 
99mTc radiopharmaceuticals is unclear and further information should be 
sought from both the Canadian regulatory authorities and the MHRA. 
 Economic assessment have shown that cyclotron production of 99mTc could 
be achieved at a cost of <$1Ca/mCi.  
 The radioactive waste implications of routine cyclotron production of 99mTc 
have not been quantified.  
 The reliability of routine large-scale production of Na99mTc04 has still to be 
demonstrated. 
 Provision of 99mTc-based radiopharmaceuticals across the UK using 99mTc 
produced in a small number of cyclotrons will likely involve a combination 
of central and local radiopharmacies in order to optimize service provision.  
There should be public sector oversight of this process. 
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UK Nuclear Medicine Workforce 
 
 Accurate information on the size of the nuclear medicine workforce in the 
UK is lacking. This is due to a number of factors including the nomenclature 
in use and the diverse ways of recording such data by the professional 
bodies. An initiative is required to collect and collate this data for the entire 
UK (not just for NHS England) for future workforce planning.  
 Despite the lack of accurate data, there is good evidence of a workforce 
shortage at all levels within the multi-disciplinary team. This is evident 
from surveys done by professional bodies, from difficulties with 
recruitment, from limited access to training pathways and from projected 
retirement of the present workforce. 
 The nuclear medicine workforce managed the challenge of past shortages 
of 99mTc, but such a response is not sustainable in the long-term. The same 
consideration applies to the wider imaging workforce outside of nuclear 
medicine, especially where alternative imaging studies are involved. 
 Technological innovations in the field of nuclear medicine have driven the 
need for further workforce training but to date initiatives to update and 
make available training programmes are at best patchy. 
 Workforce issues and training shortages within the nuclear medicine 
community in the UK cannot be underestimated – a full impact assessment 
must be undertaken as part of any move away from the traditional supply 
chain for 99mTc radiopharmaceuticals. 
 Further initiatives such as 7-day working, if applied to Nuclear Medicine, 
will put further pressure on an already stretched workforce and to be 
effective would have to be fully costed and funded. 
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Recommendations 
 
1 The critical period of 99mTc shortage is 2016 to 2020. It is uncertain to what 
extent the global initiatives described in the report will offset the impact of the 
decommissioning of the French and Canadian reactors in 2015 and 2016 
respectively but it is recommended that end-users are fully briefed with as much 
warning as possible to allow contingency arrangements to be implemented. 
 
2 The recommendations of the 2010 ARSAC Report should be implemented in 
full. To date the recommendations of the report have been deployed in part. In 
particular it is recommended that where possible, use should be made of 
resolution recovery software to permit a reduction in the activity of 
administered 99mTc and that software applications are used to improve selection 
of 99mTc generator and delivery schedules for more efficient use of the available 
resource. 
 
3 The UK as a signatory to the Joint Declaration On The Security Of Supply Of 
Medical Radioisotopes (http://www.oecd-nea.org/press/2014/2014-06.html) 
should recognise in practice the full implications of the six policy principles of 
the OECD-HLG MR mandate including a commitment to full cost recovery and 
outage reserve capacity. It is recommended that end-users, hospital 
administrators, and commissioning bodies be informed that this will mean a rise 
in the cost per unit of 99mTc. 
 
4 For strategic planning of services involving medical radionuclides in the UK, 
whether workforce or service provision-related, it is vital that that there is 
accurate information to inform decisions. At present workforce and service-
provision databases are patchy and incomplete, often providing conflicting 
information. It is recommended that the various stakeholders involved in 
nuclear medicine in the UK are encouraged to collaborate to refine databases to 
ensure accurate information in relation to workforce, imaging and non-imaging 
diagnostics, and therapy etc. 
 
5 The magnitude of the workforce issues and training shortages within the 
nuclear medicine community in the UK cannot be underestimated. It is 
recommended that a full impact assessment is undertaken as part of any move 
away from the traditional supply chain of 99mTc radiopharmaceuticals. This 
should include where appropriate an assessment of the use of alternative 
imaging (e.g. PET, CT, MR, or US) or therapy pathways, and a business case to 
estimate the costs of alternative strategies. 
 
6 It is likely that nuclear reactor fission-derived 99Mo will continue to provide the 
backbone of the future UK supply of 99mTc through the existing generator 
distribution network during the critical period. However, in context of the 
uncertainty about the future global supply of 99Mo, it is recommended that the 
UK should diversify its strategy of reliance on reactor-based 99mMo and support 
the development of novel technologies for the non-reactor production of 99mTc 
either directly or via its 99Mo precursor. Based on an assessment of the relative 
maturity of the different options and the possible co-use for purposes such as 
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manufacture of other radioisotopes, it is concluded that the most promising 
technology for the provision of 99mTc in the UK is its direct production using 
proton cyclotron bombardment at moderate energies between 18 and 24 MeV. 
 
7 99mTc production methodologies using cyclotrons with the potential to 
supplement UK demand have been identified, but would require the installation 
of high-powered cyclotrons that do not presently exist in the UK. Pioneering 
work in Canada has established the methodology and the means for 
radiochemical separation and recovery of 99mTc from 100Mo targets. 
Radiolabelling of kits and satisfactory quality control has been achieved but 
uncertainty remains around regulatory approval of cyclotron-produced 99mTc, 
the continued use of existing licensed kits, the clinical utility of the products and 
routine large-scale production and distribution has yet to be demonstrated. 
Given the time scale involved, it is recommended that UK seeks to work with 
industrial partner(s) to explore the possibility of commissioning cyclotron(s) 
with the capacity to supplement the supply of 99mTc tracers and PET 
radiopharmaceuticals. 
 
8 Provision of 99mTc based radiopharmaceuticals across the UK using 99mTc 
produced in a small number of cyclotrons will likely involve a combination of 
central and local radiopharmacies in order to optimize service provision.  It is 
recommended that there is public sector oversight of this process. 
 
9 The visit to Canada opened up a number of opportunities for collaboration and 
research in the area of medical radioisotopes. It is recommended that these 
opportunities for collaboration and research be followed up. This may also mean 
co-operation through international bodies such as the European Union and the 
International Atomic Energy Agency. 
 
10 It is recommended that a national strategy for the use of radiotherapeutics for 
cancer treatment should be developed to address the supply of 
radiotherapeutics, projected costs of drugs and resources, the clinical 
introduction of new radioactive drugs, national equality of access to treatments 
and resource planning. Consideration should be given to centres of excellence 
supporting satellites. 
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Chapter 1: The Molybdenum Supply 
Chain 
 
Brian Neilly and Alan Perkins 
1.1 Background 
 
The global shortage of 99Mo/99mTc in 2008/2009 was a wake up call and a 
reminder of the vulnerability inherent in the global supply chain for 99mTc [1], 
the principal radioisotope used for medical imaging worldwide. At the time 
notifications from the generator manufacturers to the end-user were not unusual 
(Figure 1.1). 
 
  
 
Figure 1.1 Example of a timetable of availability of generator from 
manufacturers to end-users 
 
The OECD-HLG in response to the shortage of medical radioisotope 
commissioned two mandates (2009-11 and 2011-13) and has embarked on a 
third mandate (2013-15). Arising from these initiatives the OECD NEA has 
published a series of papers addressing comprehensively the issues posed by the 
global shortage of 99Mo [1-15]. The HLG developed six policy principles that have 
been agreed to by all major 99Mo-producing countries as follows: 
 
1. All 99mTc supply chain participants should implement full cost recovery; 
2. Reserve production capacity should be sourced and paid for by the supply 
chain; 
3. Governments should establish a proper environment for efficient and safe 
market operations, without intervening directly; 
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4. Governments should facilitate the conversion to low-enriched uranium 
(LEU) by reactors and processors; 
5. International collaboration should continue through a policy and 
information-sharing forum; 
6. Periodically review the supply chain’s progress towards economic 
sustainability and security of supply. 
1.2 Global Demand for 99Mo/99mTc 
 
The OECD NEA undertook an assessment of the long-term global demand for 
99mTc [1] using an online survey that obtained 713 responses from 52 countries. 
This survey confirmed that, notwithstanding the reduced demand for 99Mo after 
the 2009 shortfall, the forecast is that demand for 99Mo will continue to grow at 
approximately 2% per annum until 2020 and then level off to a growth rate of 
1% per annum until 2030 (Figure 1.2) 
 
 
Figure 1.2 Derived from OECD NEA Report in ‘The Supply of Medical 
radioisotopes: an assessment of Long-term Global Demand for Technetium-99m’ 
[1]. Quantities are demand for 99mMo activity in 6-day Curies per week 
 
In 2010 the global demand for 99Mo was estimated at 12,000 6-day Curies per 
week (i.e. more than 500,000 per year). The 6-day Curie (6-day Curies) is the 
accepted term used to describe molybdenum activity and is the measurement of 
the amount of 99Mo activity remaining six days after it leaves the processing 
facility (end of processing (EOP)). Of this global demand for 99Mo, the regional 
demand is dominated by North America; 53% of 99Mo goes to the North 
American Market, 23% to the European Market, 20% to Asia and 4% to the rest 
of the World [16]. 
 
The 2014 report from the OECD Nuclear Energy Authority (14) revised the 
estimate of global demand for 99Mo down from 12,000 to 10,000 6-day Curies, an 
estimate compiled from data returned from vendors and users. This downturn in 
global demand is thought to have arisen from the impact of contingency 
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measures adopted by users in response to the shortages in 2009/2010 and that 
then persisted. These include improved efficiency of use and distribution of the 
radioisotope, and the use of some alternative diagnostic pathways. 
 
A number of trends were noted in the survey that may influence the future 
demand for 99mTc: 
 
 Growing population and urbanisation will drive growth in access to 
imaging; 
 Ageing population and changing prevalence of medical conditions including 
malignancy will influence demand; 
 Increased availability of SPECT and SPECT-CT cameras; 
 Expected shift from SPECT to PET - but it is anticipated that the impact of 
this will be low at least in the short-term; 
 Impact of new PET tracers may have an influence but because of the cost of 
PET imaging the relative impact will be low in the short to medium-term. 
While there is less certainty about the predicted accuracy of the estimates by 
2030, most authorities agree that there will be a continued growth in demand for 
99Mo in the medium term before then. Estimates drawn from a number of 
sources [2, 17-19] reveal that in the short to medium term, 99mTc is expected to 
remain the major market player although the relative proportion of the 
radiopharmaceutical market occupied by 99mTc is expected to decrease (from 
85% to 72%). The absolute size of the market is expected to increase in the short 
to medium term (Figure 1.3).  
 
 
 
Figure 1.3 Anticipated change in the global radiopharmaceutical market. 
Estimates vary according to source [2, 17,18] but are of a comparable amount. 
Another report estimates a rise in the global radiopharmaceutical market from 
$3.8 billion in 2012 to $5.5 billion in 2017 [19] 
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1.3 The Molybdenum 99 Supply Chain 
 
The shortage in availability of 99mTc for diagnostic imaging is due to the 
complexity of the supply chain that involves many steps, each with the capacity 
for fragility (see Figure 1.4). The following section highlights the various steps in 
the supply chain involved in the manufacture and distribution of 99Mo. This 
involves a number of steps as follows: 
 
 Uranium target manufacturer; 
 Target irradiation in a suitable nuclear reactor; 
 Processing to dissolve the irradiated targets and chemically extract 99Mo; 
 99Mo/99mTc generator manufacturer; 
 Elution of 99mTc from the generators and prepare radiopharmaceuticals in a 
radiopharmacy; 
 Transport of radiopharmaceuticals to the end user clinics. 
At each point in the supply chain there are issues that have to be addressed. 
These issues are set out below. 
 
 
 
Figure 1.4 Simplified depiction of supply chain in the conventional production of 
99mTc using reactor fission (reproduced from OECD NEA Document ‘The Supply 
of Radioisotopes: The Path to Reliability, 2011” [6]) 
1.3.1 Uranium Targets 
At present the majority of nuclear reactors use highly enriched uranium (HEU) 
targets for the manufacture of 99Mo and also in the reactor fuel itself. Of those 
listed (Table 1.1) only OPAL, RA3 and Safari-1 use low enriched uranium (LEU) 
targets. To meet present and future non-proliferation demands, all current 99Mo-
producing nations have agreed to convert from using HEU to LEU targets for 
99Mo production. The American Medical Radioisotopes Production Act 2012 
extends previous non-proliferation efforts and includes provisions to restrict the 
export of HEU from the United States for the purposes of medical isotope 
production by 2020. It is anticipated that LEU conversion will have a potential 
impact on the global supply chain both in terms of capacity and costs. In 
recognition of this the HLG-MR undertook and published a report on the market 
impacts of converting to LEU Targets for medical isotope production (15). The 
advantages of LEU over HEU include: greater proliferation resistance; in 
consequence an easier availability of target material; and better compliance for 
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target transportation and processing. There are also some downsides, including 
the fact that around 5 times more LEU must be used than HEU for a given 
production of 99Mo, with approximately 25 times more 239Pu is produced when 
using LEU targets. However, it is anticipated that the operating costs when 
producing LEU-derived 99Mo will be more or less the same as for HEU. The main 
burden for the producers will be the time and costs associated with the 
conversion and the increased volumes of radioactive waste. The HLG-MR report 
recognized that LEU conversion would reduce available irradiation and 
processing capacity in the interim, but was unlikely to cause long-term 
shortages. Overall, LEU-based 99Mo is likely to be more expensive that HEU-
based 99Mo. Nevertheless, all major producers have committed to converting to 
LEU targets by 2016 and LEU-based 99Mo is gaining acceptance in markets 
traditionally supplied with HEU-based material. For example, to encourage use 
of non-HEU derived 99mTc in the US, an additional $10 payment is mandated for 
each patient radiopharmaceutical administration that is derived from LEU 
sources. 
1.3.2 Nuclear Reactor Supply:  
At present a small number of research nuclear reactors are involved in the large-
scale global supply of 99Mo on an industrial scale (see Table 1.1). These reactors 
are NRU (Canada), BR-2 (Belgium), HFR (Netherlands), OSIRIS (France), 
SAFARI (South Africa), MARIA (Poland), LVR-15 (Czech Republic), OPAL 
(Australia), RA-3 (Argentina) and FRM-II (Germany). As can be seen from the 
Table 1.1, most of the world’s 99Mo comes from only five research reactors, 
namely Canada’s NRU, the Netherlands’s HFG, Belgium’s BR-2, France’s Osiris 
and South Africa’s Safari-1 reactor. The majority of these reactors are >40 years 
old and, in keeping with this and poor investment, are subject to unexpected and 
prolonged shutdowns. In some cases there will be permanent shutdowns. A brief 
summary of reactor operations is given below. 
 
Table 1.1 Current reactor production of 99Mo 
 
Reactor Country Target Normal 
Operating 
Days 
Normal 
capacity per 
week 
(6-d Ci) 
Potential 
annual 
production 
(6-d Ci) 
Estimated 
date to 
cease 
production 
BR-2 Belgium HEU 140 7,800 156,000 2026 
HFR Netherlands HEU 280 4,680 187,200 2024 
LVR-15 Czech Rep HEU 210 2,800 84,000 2028 
MARIA Poland HEU 210 2,200 42,900 2030 
NRU Canada HEU 280 4680 187,200 2016 
OPAL Australia LEU 300 1,000 42,900 2055 
OSIRIS France HEU 182 2,400 62,400 2015 
RA-3 Argentina LEU 336 400 19,200 2027 
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SAFARI South Africa HEU-
LEU 
305 3,000 130,700 2025 
 
* Based on operating days and normal available capacity – not necessarily what 
is actually produced currently. (Reproduced from (OECD –NEA Report 2014[14]) 
 
BR2, Belgium: BR2 undertook additional irradiation cycles during April and 
May 2013 to compensate for the reactor problems causing outage of HFR 
(Petten). The authorities requested stress tests of BR2 in 2013 following the 
Fukushima incident; implementation of this work is scheduled during 2013-
2016. The next operating license period will be for the period 2016-2026; a 
safety review will be due by 2016. A major maintenance and design update  - 
including the replacement of the beryllium matrix - will be undertaken with a 
shut down of up to 16 months commencing March 2015. Restart of the reactor is 
scheduled for July 2016. The operator SCK.CEN plans to construct and operate a 
new research reactor (MYRRHA), an Accelerator Driven System that aims to be 
operational from 2024. This new facility is intended for nuclear technology 
research and isotope production as a replacement for the BR2 reactor. 
 
HFR Petten, Netherlands: HFR was out of action for eight months during 2012-
13 (tritium contamination was found in groundwater due to cooling pipe 
leakage). The reactor was restarted in June 2013 with new operating systems in 
place. It is intended that HFR will remain operational until a new Dutch reactor is 
built at the Petten site. The operator NRG plans to construct and operate a new 
reactor (PALLAS) that aims to be operational from 2024. This new facility is 
intended for isotope production and nuclear technology research. The Dutch 
government have pledged (in October 2014) a loan of €30 million to keep the 
HFR reactor operational until 2024. 
 
LVR-15, Czech Republic:  LVR-15 has responded to the global shortage and 
increased production capacity of 99Mo. This has helped offset the shortages in the 
market from the other sites although is only likely to be operational in the short 
to medium term. 
 
Maria, Poland: As per LVR-15 above. 
 
NRU, Canada: Prior to 2008 NRU was the major world producer of 99Mo, 
responsible for 40-50% of global demand through Nordion Inc. (Ottawa, 
Canada). Due to licensing problems preventing operation, in 2008 Atomic Energy 
Canada Ltd (AECL) was forced to cancel the replacement reactors for NRU, 
MAPLE-I and MAPLE-II (Multipurpose Applied Physics Lattice Experiment). The 
MAPLE reactors had the potential to supply the entire global needs of 99Mo as 
well as supplying 131I, 125I and 133Xe. Short-term provision of 99Mo will be 
maintained at NRU until November 2016 after which the facility will cease 
operation permanently. 
 
OPAL, Australia: A new research reactor, known as OPAL (Open Pool Australia 
Light water reactor), was opened in 2007. OPAL is a 20 MW open-pool design 
using both LEU fuel and targets. At present OPAL supplies mainly the Australian 
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domestic market, however further investment has enabled additional processing 
and waste capacity to increase production to also supply into the Asian and US 
markets. 
 
OSIRIS, France: In 2011 the French regulator Autorité de Sûreté Nucléaire 
(ASN) determined that the OSIRIS Reactor would continue operation until 2015 
but would close no later than the end of 2015 in compliance with the ASN 
decision of 2008. The French are currently building a new 100 MW materials-
testing reactor (Jules Horowitz) at Cadarache in southern France. This reactor is 
not expected to be operational until at least 2021. 
 
SAFARI-1, South Africa: Conversion of the 20 MW SAFARI-1 reactor at NESCA’s 
Pelindaba facility to LEU fuel was completed in 2009 with the introduction of 
LEU-based targets for isotope production. The first radioisotopes produced by 
SAFARI-1 were shipped to international customers in July 2010. 
1.3.3 Processors 
It can be seen from Tables 1.1 and 1.2 and from Figure 1.5 that the global supply 
of 99Mo is dependent on a small number of research reactors and processing 
facilities. Currently, six processors are involved in the production of 99Mo on a 
globally significant scale. These include AECL/Nordion (Canada), ANSTO 
(Australia) and MALLINCKRODT (Netherlands). Regional limitations on 
processing capacity can limit the full use of reactors during outage situations. It 
is understood that AECL/Nordion will cease processing after the closure of NRU 
Canada. 
Table 1.2 Current processors of 99Mo 
 
Processor Country Target Capacity per 
week 
(6-d Ci) 
Annual 
Capacity 
(6-d Ci)* 
Expected date 
of conversion 
to LEU targets 
AECL/NORDION Canada HEU 4,680 187,200 Not expected 
ANSTO HEALTH Australia LEU 1,000 52,000 Started LEU 
CNEA Argentina LEU 900 46,800 Converted 
MALLINCKRODT Netherlands HEU 3,500 182,000 2017 
IRE Belgium HEU 3,500 182,000 2016 
NTP South Africa HEU/LEU 3,500 182,000 2014 
 
* Actual production is often less, as processing capacity is technically available 
52 weeks while irradiated targets are not delivered 52 weeks of the year for all 
processors. This may have the effect of some processing capacity not being fully 
used if there is not sufficient irradiator capacity to supply the processor with 
irradiated product (Reproduced from (OECD –NEA Report 2014[14]) 
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Figure 1.5 Diagram showing the Molybdenum-99 distribution network from 
producer to end-user 
1.4 Full-Cost Recovery and Outage Reserve Capacity 
 
The origins of the radioisotope supply issue reside in the past use of research 
nuclear reactors that were developed exclusively using 100% funding from 
national governments, and primarily for nuclear materials research. 99Mo was 
initially a by-product of the main reactor activity, and when the importance of 
99Mo increased there was no corresponding sustainable economic assessment or 
pricing to reflect the proper contribution to production costs and deterioration 
of equipment. The revenues to 99Mo producers remained small whilst demands 
increased, and tariffs were set by long-term contracts. This meant that 
increasingly the governments of 99Mo-producing countries effectively subsidized 
foreign healthcare systems and the companies supplying them. There was 
therefore no incentive for investment as those reactors aged and became 
increasingly vulnerable to outages and closures. Furthermore there was no 
incentive to participate in outage reserve schemes to mitigate the impact of 
unforeseen and unexpected closures of those same production facilities. 
 
In recognition of the importance of production economics to the future secure 
supplies of radioisotopes, the OECD HLG-MR recommended that economic 
return must be improved compared to economic model in existence. In 
particular, it was recommended that reactors should operate their 99Mo 
production on a full-cost-recovery basis so that outage reserve capacity is 
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provided, valued and recompensed to the producers. The following definitions 
were adopted: 
1.4.1 Full-Cost Recovery (FCR) 
All costs associated with producing 99Mo are identified and covered through 
prices set for irradiation services. This should include both the operational and 
capital costs. FCR will increase 99Mo prices to healthcare providers significantly 
although the increase will be much smaller at the hospital end-user level. Higher 
prices at reactors must be passed on throughout the supply chain. FCR is 
important for economic sustainability and security of supply and to encourage 
new and ongoing investment in future 99Mo production capacity. 
1.4.2 Outage Reserve Capacity (ORC) 
OCR is defined as the capacity within the system to account for occasional 
unplanned or extended shutdowns of reactors. Processors should hold ORC 
equal to at least their largest source in the supply chain (n-1 criterion). Market-
based ORC prices allow for full cost recovery. ORC costs are expected to cover 
transaction and fixed capital and operational costs. Exercising an ORC option in 
the market will trigger additional payment for variable costs. 
 
The scale of the problem associated with the economic model presently used in 
financing the global supply of 99Mo/99mTc is illustrated in Figure 1.6. It is 
acknowledged by the OECD NEA HLG-MR that this financial model is not 
sustainable. Inevitably the cost of 99mTc per unit to the end-user will have to 
increase. 
 
 
Figure 1.6 Problem associated with the present financial model used to support 
global Molybdenum distribution (Courtesy of Piet Louw, NTP) 
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1.5 Future Demand and Supply 
 
As outlined above, and based on returns from national surveys, the OECD-NEA 
estimates that demand for 99Mo/99mTc will continue to rise within the forecast 
period out to 2030. The rate of rise will be different in the mature compared to 
the developing markets; within the mature markets, the need for 99Mo/99mTc will 
increase at a rate of 0.5% per annum whereas the forecast for the developing 
markets is of the order of 5%. There are a number of factors contributing to this 
overall rise in demand including an increasingly older population and an 
increasing prevalence of dementia and malignancy.  
 
The estimate of the true global demand for 99Mo/99mTc also needs to incorporate 
a requirement for outage reserve capacity (ORC). It is not possible to measure 
ORC directly as outages are often unpredictable. The HLG proposal was that a 
processor should hold sufficient reserve capacity to replace the largest supplier 
of irradiated targets in the supply chain (the n-1 criterion). Experience has 
shown that the additional need to cope with supply outages lies somewhere 
between the n-1 and the n-2 criterion. This translates to an additional 35% to 
62% capacity as shown in green and red lines in the accompanying graphs 
(Figures 1.7, 1.8, 1.10). 
 
Since 2009, a number of initiatives have developed options, both reactor-based 
and non-reactor based, that hold out promise to maintain/increase the 
availability of 99Mo/99mTc. The following information derived from the 2014 
OECD-NEA Report (14) provides an update on irradiator and processing capacity 
now and in the future. 
1.5.1 Present Global Irradiator Capacity 
As shown (Figure 1.7) the assumption is that the global demand for 99Mo/99mTc 
will continue to rise throughout the prediction period 2015 to 2020 (line labeled 
‘Demand with no ORC’). As shown global 99Mo capacity (Line labeled ‘Current 
irradiation Capacity’) is predicted to be sufficient prior to the start of the BR-2 
refurbishment project in 2015, after which it drops sharply as there is no 
immediate replacement. The sustained fall also reflects the loss of output from 
the OSIRIS reactor due to close in 2015. 
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Figure 1.7 Current irradiation capacity and demand for the forecast period 
2015-2020 based on the current fleet of irradiators (Reproduced from (OECD –
NEA Report 2014[14]) 
 
The increase in irradiation capacity in the second half of 2016 reflects the 
planned resumption of service from BR-2. The drop in capacity during the first 
part of 2017 reflects NRU’s exit from the global supply chain in 2016. Assuming 
there is no additional input to the supply chain, the supply and demand lines 
converge introducing a significant risk of a shortfall of supply and substantially 
below the desired ORC. The ageing fleet of reactors, the impact of LEU 
conversion and the uncertainty as to whether operating licenses will be 
extended all increase the likelihood of shortfall in supply. 
 
Based on the above considerations it is clear that it will be necessary to identify 
additional sources of 99Mo/99mTc supply. 
1.5.2 Present Global Processing Capacity 
The rate-limiting factor in the supply chain for 99Mo is not confined to irradiator 
capacity but also is dependent on processing capacity. The reasons for this 
include the lack of on-site processing facilities at some reactor sites, and the loss 
of AECL/Nordion’s processing facility with the closure of NRU in 2016. 
 
As shown in Figure 1.8, processing capacity keeps pace with irradiation capacity 
until late 2016 when NRU closes and BR-2 re-enters the market.  Unless there 
are new processing facilities it is predicted that there will be a gap between 
irradiation and processor capacity in the forecast period 2015-2020. It is also 
clear from Figure 1.9 that the years 2016 to 2017 will be a period when 
processing capacity falls below the ORC (Demand + ORC) line and therefore 
there could to be insufficient supply during this time. Thereafter, and assuming 
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new irradiator and processing capacity comes on line, the total processing 
capacity appears sufficient to supply global demands. 
 
Figure 1.8 Projected processing capacity compared to irradiation capacity and 
demand, 2015-2020 (OECD NEA 2014[14]) 
 
Figure 1.9 Processing capacity compared to irradiation capacity and demand, 
2015-2020 (OECD NEA 2014[14]) 
1.6 Global Initiatives To Address The Supply Problem 
 
Possible paths to sustained availability of 99mTc for medical imaging have been 
summarized in recent publications [20]. Individual nations have responded 
variously to the problems in the supply chain and as a result of the HLG-MR 
 31 
initiative, a number of different strategies are being pursued, some already 
underway, and some yet to commence. These are summarized in Table 1.3 and 
further detail is provided in Appendix 1.1 for each site. 
 
Table 1.3 National programmes for additional Molybdenum 99 capacity 
 
Reactor Targets Weekly 
capacity (6-d 
Ci) 
Annual 
production (6-
d Ci)
1
 
Estimated 
start date 
Status 
RIAR (Russia) HEU in CRR* 1200 60000 2015 Started 
Karpov Institute HEU in CRR* 300 14800 2015 Started 
NORTHSTAR/MUR
R (USA)  
Non-
fissile/CRR*  
2750/3000 39100/156400 2015/17 Phase 1 
MORGRIDGE/SHIN
E (US)  
LEU solution 
with DTA* 
3000 144000 2017 NYS* 
NORTHSTAR 
(USA)  
Non-fissile 
LINAC* 
3000 144000 2018 NYS* 
FRM-II (Germany)  LEU in CRR* 1 600 54300 2017 Started 
OPAL LEU in CRR* 2600 111400 2017 Started 
KOREA  LEU in CRR* 2000 85700 2018 NYS* 
CHINA Advanced 
RR  
LEU in CRR* 1000 50000 2019 Modification 
Brazil MR  LEU in CRR* 1000 41400 2019 Preliminary 
RA-10 (Argentina)  LEU in CRR* 2500 120000 2019 Preliminary 
Jules Horowitz RR 
(France)  
LEU in CRR* 3200 100600 2020 Under 
Construction 
 
*CRR = conventional research reactor, DTA = deuterium-tritium accelerator, HEU 
= highly enriched uranium, LEU = low enriched uranium, LINAC = linear 
accelerator, NYS = not yet started, 6-day Ci = 6-day Curie 
1.6.1 Potential impact of the new global initiatives 
The potential impact of these new reactor-based initiatives is illustrated in 
Figure 1.9, taken from the latest OECD Report [14]. It can be seen that, assuming 
entry into the market of new sources of 99Mo/99mTc, global irradiation capacity 
will remain above the lower ORC estimate of 35% but below 62% ORC during 
2015 to 2016. During this period there is the potential for demand to outstrip 
supply.  
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Later in the forecast period it is anticipated that there will be an upturn in 
irradiation capacity due to commissioning of new reactor capacity particularly in 
South America and in Asia. The graphs separate conventional (reactor-based) 
from total irradiation capacity due to the fact that alternative methods of 
99Mo/99mTc production have not yet been used on a large-scale basis. 
 
The model of production and supply of medical radioisotopes is vulnerable to 
disruption at many points along the supply chain. It is therefore vital that new 
strategies are developed to secure future supplies. Further details of options for 
alternative strategies towards sustainable radioisotope availability have been 
published in a recent article in the Journal of Nuclear Medicine [20] and further 
details are discussed in Chapter 4 of this report.  
 
 
 
 
Figure 1.10 Current and selected new irradiation capacity and demand, 2015-
2020 (OECD NEA 2014) 
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1.7 Non-Reactor Initiatives 
 
Some countries are exploring non-reactor based solutions for the supply of 
99mTc. Following the decision to shut the NRU reactor the Canadian government 
invested $35 million between 2010 and 2012 from the Non-reactor-based 
Isotope Supply Contribution Program (NISP) and supported R&D of 99Mo/99mTc 
production using cyclotrons and other methods. The objectives were to diversify 
sources of isotope supply to reduce radioactive waste and to eliminate the use of 
HEU. In the period 2012-2016, the Canadian Government is investing a further 
$25 million to further develop cyclotron and linear accelerator technologies for 
the production of 99mTc on a commercial basis by 2016. Research and 
development activities are focused on the development of commercial, cost-
efficient production of 99mTc using high current cyclotrons (for example using 
the 19 and 24 MeV models manufactured in Canada by Advanced Cyclotron 
Systems Inc.). Because it is a direct production method, the cyclotrons must be 
based as a network in which the distribution distance by vehicle is no more than 
around 4 hours. An advantage of cyclotrons over some other non-reactor 
methods is that they can produce not only 99mTc, but also a wide range of other 
PET and SPECT radioisotopes such as 18F, 64Cu, 123I, 124I, and 68Ga. This advantage 
is particularly relevant in the UK, and the national situation here is described in 
detail in Chapter 2. 
1.8 Conclusion  
 
From the foregoing discussion it can be seen that there is the potential for 
shortage of 99mTc to the global market from 2016 through to 2020. The exit of 
NRU and OSIRIS from the market will be offset to an extent by the resumption of 
increased production at BR2 during 2016 and the fact that funds have been 
committed to keep HFR in production in the short to medium term. It is likely 
that other reactors will come on line but time scales are difficult to estimate and 
these are subject to frequent revision. The Maria and LVR reactors have been 
able to increase production in the short term. The situation is fluid and the 
estimates of the 99Mo supply are subject to change. For example the Australian 
Nuclear Science and Technology Organization (ANSTO) has recently announced 
that a $168.8 million investment by the Australian Government will enable it to 
increase production to supply up to 25 to 30% of global demand [21]. This is 
likely to serve the needs of the southern hemisphere and given the uncertainties 
that persist in relation to demand and supply, it is recommended that the UK 
should explore alternative options for supply of its medical radioisotopes to 
maintain clinical nuclear medicine services. The following chapters discuss what 
measures are already in place in the UK and what options are available to 
mitigate the impact of the anticipated shortages that will arise from the reactor 
and processor changes that have been outlined above. 
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Appendix 1.1 Initiatives of Individual Countries 
 
Russia is developing additional irradiation and processing capacities although 
the contribution to the global market remains uncertain. Recently 99Mo produced 
in Russia has been assessed as being of suitable quality to meet western 
regulatory standards.  
 
USA. The US Department of Energy established a partnership with four US 
commercial companies to facilitate the establishment of independent 
technologies to produce 99Mo without the use of HEU. These are as follows: 
 
(i) Babcock & Wilcox in collaboration with Covidien has worked on the 
development of a Medical Isotope Production System (MIPS) to produce 99Mo by 
irradiation of LEU fuel in solution in a low power 240 kW Aqueous Homogenous 
Reactors. Covidien withdrew from the project in October 2012 as the project was 
thought to be commercially non-viable. 
 
(ii) GE-Hitachi completed a conceptual design to produce 99Mo in BWR power 
plants by the neutron capture reaction 98Mo(n,y)99Mo. However, GE-HITACHI 
decided in February 2012 to suspend progress on the project due to market 
conditions. 
 
(iii) NORTHSTAR is working on two projects to produce 99Mo: 
(a) Production of 99Mo in MURR (Missouri University Research Reactor) by 
neutron capture (98Mo(n,y)99Mo) on natural and/or enriched 98Mo 
targets. Production is expected to start in early 2014 and could be 
upgraded to 3000 Ci(6-d) per week by 2016. 
(b) Production of 99Mo by photonuclear production (100Mo(y,n)99Mo) using 
a 24 MeV electron linac is also planned from 2016. Both technologies 
produce low specific activity 99Mo that will require improvements to 
generator design. 
(iv) SHINE Medical Technologies plans to produce 99Mo in a subcritical LEU 
solution where fission is driven by an intense D-T neutron source. A low-energy 
deuterium beam is directed onto a tritium-loaded target to obtain fast (14 MeV) 
neutrons that are then moderated in a beryllium prior to entry into the LEU. 
SHINE expects to start commercial operations in mid 2016 with a licensed 
capacity of about 3000 Ci (6-d) per week from a single accelerator. 
 
FRM-II, Munich, Germany. The FRM-II reactor in Munich has a project to install 
new equipment for the irradiation of LEU targets from 2015 depending on target 
availability. This project can be seen as a replacement for the 99Mo production in 
Julich by the FRJ-2 reactor that was shut down permanently in 2006. The FRM-II 
research reactor is looking to irradiate LEU targets for 99Mo production using the 
processing facility at IRE (Belgium). Transport arrangements are currently 
under consideration. This is unlikely to contribute to pharmaceutical grade 
production before 2017. 
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OPAL, Australia. The OPAL reactor (Lucas Heights) covers current national 
needs by the irradiation of LEU targets. Australia is building a new processing 
and waste facility with full production that is expected to start in 2016 providing 
3500 6-d Ci per week. ANSTO’s 99Mo produced from LEU targets is already FDA 
approved in the US. 
 
Korea. Korea has announced $3B (US) government funding for a project to 
provide self-sufficiency in medical welfare. Presently there is a conceptual design 
for two parallel irradiation lines with five hot cells for production of 2000 Ci per 
week although there are no firm plans for construction. 
 
China. The demand for 99Mo/99mTc is increasing in China. A 6MW reactor (CARR 
– China Advanced Research Reactor) has been operating since 2008 for medical 
radioisotope production. The range of materials produced includes 99Mo, 125I, 
131I, 177Lu, 90Y, 14C and 188W. 
 
Brazil. At present all 99Mo is imported. There is a plan to develop a 30MW 
multipurpose open pool reactor in cooperation with Argentina for production of 
1000Ci 99Mo per week to satisfy domestic demand; the project is based at the 
Aramar Technological Centre in the State of Sao Paulo. Funding is to be provided 
from government and private partnership (around $500M US). 
 
France. The license of the OSIRIS (France) reactor expires at the end of 2015. 
The new Jules Horowitz (JHR) reactor under construction in Cadarache will 
replace the OSIRIS reactor. Started in 2011, the reactor dome was put in place 
during 2013. It is planned to start operation in 2017 with production of 99Mo by 
2020/21. JHR is expected to have the potential to provide up to 50% of European 
needs irradiating 32 to 48 targets per week giving up to 2400 6-day Ci per week. 
 
Belgium. SCK.CEN plans to upgrade its BR2 reactor operating regime from 
five/six to up to eight operating cycles per year after a refurbishment, depending 
on the economics of production; BR2 currently operates 120 to 140 days per 
annum but from 2016 could operate from 180 to 200 days per annum. 
Refurbishment will allow operation until 2026 or until the start of the 
replacement facility MYRRHA scheduled to start operation in 2024. 
 
Argentina. The Argentinian RA-10 30 MW reactor intends to satisfy the 
increasing national and regional demands for medical radioisotopes. The 
operator CNEA supports it through $200 million national funding (‘Applications 
of Nuclear Technology in Health Industry and Agriculture’). RA-10 is planned to 
be operational by the end of 2018. The project plans a radioisotope processing 
and manufacturing facility with capacity for 2500 Ci 99Mo per week plus 
production of 131I. This will largely cater for the domestic and South American 
market. 
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Chapter 2: Nuclear Medicine in the UK 
Brian Neilly and Alan Perkins 
Summary 
 
 Nuclear Medicine as currently practiced in the UK is a multidisciplinary 
specialty employing a workforce of more than 2,500 individuals 
 There has been a significant increase over time in the NHS of the 
availability of gamma cameras with SPECT and SPECT-CT capability. 
These cameras are optimal for imaging using 99mTc-based radiotracers. 
 The demand for conventional (non-PET) imaging and non-imaging 
diagnostics in the UK is in the region of 600,000 per annum. Bone, cardiac 
and renal investigations make up more than half of the requests for these 
investigations. 
 There is an increasing availability of PET-CT across the UK for a growing 
number of indications. In most of these centres there is limited capacity 
for further growth due to high use for FDG-PET-CT for oncological 
indications. Non-oncological and non-FDG PET indications presently 
make up only 10% of the total. 
 The cyclotrons available in the UK for the production of 18FDG and other 
PET-tracers are not suitable for the large-scale production of 99mTc. 
Higher-energy cyclotrons would have to be installed if commercial 
quantities of 99mTc are to be produced.  
 Nuclear medicine services in the UK receive generators from only three 
commercial companies. The majority of radiopharmacy services in the UK 
have been affected by generator shortages. 
 Most nuclear medicine services in the UK have developed contingencies 
to deal with periods of shortage. These include re-scheduling the patient, 
employing alternative radiopharmaceuticals, or using lower administered 
activities, none of which are optimal. In a small proportion of cases this 
change has affected future patient referrals. 
 There is evidence of unnecessary waste of radioactivity arising from the 
current generator delivery schedules to departments. Delivery and 
elution schedules for 99mTc generators are highly complex and software 
options exist to facilitate the correct choice. This could be improved 
through partnerships with the commercial generator suppliers. 
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2.1 Introduction 
 
The UK, like other countries, has been affected by the global shortage of 99Mo and 
99mTc as well as experiencing shortages of other reactor-derived radioisotopes 
such as 131I. Arguably the UK is more vulnerable to breaks in the supply chain 
since there is no domestic production either of 99Mo or of 99mTc. Breaks in the 
supply chain can occur at reactor, processor or generator manufacturer stages 
with additional disruption possible during transportation to the UK. The use of 
medical radioisotopes in the UK is not restricted to 99mTc but includes other 
radiopharmaceuticals including radioisotopes of iodine, indium and also PET 
radioisotopes other than FDG. The past 10 years has seen an increasing 
availability of PET imaging facilities. This chapter aims to review the present 
status of nuclear medicine services in the UK. 
2.1.1 Nuclear Reactors 
There are no nuclear reactor target irradiation or molybdenum processing 
facilities for medical radioisotope production within the UK. As far as can be 
ascertained there are no plans to build a research nuclear reactor in the UK for 
or any other civilian nuclear purpose. Even in the event that a research reactor 
was proposed for these purposes the lag between proposal and the manufacture 
of radionuclides is considered to be up to 10 years. Given the timescales of 
shortages and the clinical need, the option of a research reactor has therefore 
been discounted in this report. 
2.1.2 Generator Suppliers 
The UK relies exclusively on the importation of 99Mo/99mTc generators or 
processed bulk molybdenum (for generator manufacture at the GE plant at 
Amersham) from overseas. Three companies distribute 99mTc generators to 
vendors throughout the UK: GE Healthcare; IBA/Alliance; and Mallinckrodt 
Pharmaceuticals. The share of the UK market for 99mTc generator supply is in the 
region of 40%, 30% and 30% for GE, IBA/Alliance and Mallinckrodt 
Pharmaceuticals respectively. Generators are distributed to approximately 150 
outlets in the UK; these outlets include central radiopharmacies and individual 
hospital departments. The generator suppliers source their raw material for 
generator manufacture from several suppliers and have in place contingency 
arrangements to attempt to secure supplies in times of shortage. Communication 
with the generator suppliers to the UK market to inform customers of 
anticipated times of shortage has improved in recent years allowing end users to 
invoke contingency measures to maintain clinical services.  
 
The objectives in this section are to provide a snapshot of nuclear medicine in 
the UK and to provide an overview of how it is practiced. Data is drawn from 
several sources including the British Nuclear Medicine Society (BNMS) national 
survey and the UK Radiopharmacy Services Review in 2012. 
 
The chapter also describes the current status of PET radiopharmaceuticals and 
cyclotrons for the production of PET tracers in the UK. It also sets out the 
initiatives that have been undertaken to mitigate the impact of shortages of 99mTc 
and other reactor derived radioisotope.  
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2.2 BNMS Survey 2010 
 
The BNMS survey is a web-based resource offering an ongoing annual snap shot 
of nuclear medicine within the UK. The last survey was undertaken in 2010 and 
was completed by 132 out of 210 (62%) known nuclear medicine departments. 
Data from a recent scoping exercise undertaken as part of the ongoing BNMS 
survey re-design is that the true estimate of NHS departments in the UK offering 
nuclear medicine services is in excess of 300. This fact, coupled with the 
participation of only 62% of departments in the 2010 BNMS survey means that 
the 2010 data likely represents an under-estimate of nuclear medicine practice 
in the UK. Nevertheless, the data is drawn from across a wide spectrum of 
regions providing figures to provide a reasonable snapshot of current nuclear 
medicine practice.  
 
The survey was completed by participating departments from each of the 
English regions and from each of the devolved administrations including: 
England NE 6, England NW 20, Yorkshire 7, East Midlands 10, West Midlands 10, 
East of England 10, England South West 11, England South Central 9, England 
South East 9, London 23, Northern Ireland 4, Scotland 11 and Wales 3. The 
survey revealed information about the staffing (Table 2.1), equipment (Table 
2.2), the scope and number of diagnostic studies undertaken (Table 2.3), and the 
number of procedures using therapy radionuclides (Table 2.4). 
2.2.1 Nuclear Medicine Staffing 
The 2010 BNMS survey provided an estimate of the workforce employed within 
Nuclear Medicine in the UK and emphasizes its multi-disciplinary nature. 
 
Table 2.1 UK Workforce employed in Nuclear Medicine in 2010 
 
Staff Category Number of Staff 
Administrative & Clerical 331 
Clinical Practitioners (Technicians/ Radiographers) 1048 
Clinical Scientists 281 
Health Care Assistants 110 
Nuclear Medicine Clinicians 89 
Nuclear Medicine Trainees (Science + Clinician Trainees) 142 
Nuclear Medicine Radiologists 389 
Nurses 160 
Radiochemists* 10 
Radiopharmacists* 89 
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* Doubt has been expressed about the accuracy of the estimate of numbers of 
Radiochemists and Radiopharmacists in the survey. 
2.2.2 Nuclear Medicine Equipment 
While the absolute numbers of gamma cameras and PET-CT scanners is likely to 
be underestimated (see above), it can be seen that the proportion of camera 
systems with SPECT, SPECT-CT and PET-CT has increased significantly over the 
four years since 2007 (Table 2.2). The number of planar gamma cameras has 
decreased in this time.  The numbers of SPECT and SPECT-CT camera systems in 
place favour 99mTc-based detection systems rather than PET systems at this time.  
 
Table 2.2 Nuclear Medicine Equipment in the UK in 2010 
 
NM Equipment Equipment Type 2007 2010 
Gamma Cameras Planar 78 27 
 SPECT 185 240 
 SPECT-CT 36 81 
PET Cameras PET-only Few 0 
 PET-CT 12 27 
Cyclotrons NHS/University Few 8 
 Private Sector Few 5 
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2.2.3 Nuclear Medicine Procedures 
The BNMS survey provided a snapshot of the types of investigations undertaken 
using radionuclides in the UK in 2010 (Table 2.3). Also shown is the number of 
PET studies reported in the UK in 2010. The present estimate of numbers of PET-
CT procedures is now estimated to be in the region of 40-50,000 per annum. 
 
Table 2.3 Types of Investigations using Radionuclides in the UK 
 
Nuclear Medicine Diagnostic 
Studies 2010 
NM Diagnostic Studies 
excluding PET in 2010 
(Number) 
PET Imaging 
Studies in 2010 
(Number) 
Brain 11,718  
Cardiac 97,529  
Endocrinology 29,998  
Renal 74,403  
Respiratory 59,182  
Bone 218,408 81 
Oncology 5,702 19950 
Infection/inflammation 4,926  
SLNB 24,052  
GI 10,332  
Miscellaneous 62,402  
Non-Imaging Diagnostics 43,266  
Total Diagnostic procedures 673,156 20031 
 
Corroboration of UK demand for 99mTc and other non-PET radioisotopes has 
come from figures provided by industry. In 2012 industry figures estimated that 
the total number of diagnostic procedures using 99mTc, 111In, 201Tl or isotopes of 
iodine (123I, 131I), is in the region of 600,000 procedures per annum. Of these, the 
majority of procedures utilize 99mTc. As shown in Figure 2.1, the main indications 
for 99mTc-based radiopharmaceuticals are for bone, cardiac and renal 
scintigraphy. 
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Figure 2.1 Data sourced from Industry as to the breakdown of use of non-PET 
radiopharmaceuticals (mainly 99mTc) used in the UK in 2012 
 
2.2.4 Therapy Radionuclides Used in the UK 
The 2010 BNMS survey provided an estimate of the therapies undertaken in the 
UK during 2010 using radionuclides. The results are shown in Table 2.4. 
 
Table 2.4 Number of therapy procedures undertaken using radionuclides in the 
UK during 2010 
 
Radionuclide Therapy UK 2010 Number in 2010 
In-patient Radionuclide Therapy 2,842 
Outpatient Radionuclide Therapy 9,044 
Total 11,886 
 
Treatment of benign thyroid disease (chiefly thyrotoxicosis) is the most common 
indication for radionuclide therapy using 131I. In addition to this 131I and other 
beta and more recently alpha radionuclides are used in the treatment of a wide 
range of oncological and non-oncological conditions as shown in Figure 2.2. Also 
shown are the numbers of centres in the UK involved in the administration of 
such therapies. This is expected to increase substantially with the introduction of 
223Ra. 
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Figure 2.2 Types of therapy using radionuclides (excluding 131I for benign 
thyroid disease) and number of participating UK centres 2012. 
2.3 Radiopharmacy Services Review 2012 
 
In the context of the recurrent shortages of medical radioisotopes, a survey of 
radiopharmacy services in the UK (2) was carried out by the BNMS by contacting 
all UK nuclear medicine departments held on a central contact list. Units were 
invited to respond to an online questionnaire managed through Survey 
MonkeyTM between 3 and 31 October 2012. 
 
The survey was completed by just over half of the 222 Nuclear Medicine 
departments known in the UK. More than two thirds of the responding 
departments (71.2%) held a manufacturing license with the MHRA. All 
departments received 99mTc from a generator or a multi-dose vial. Of the 
departments responding, none stated that they received 99mTc prepared as 
individual patient doses. 
2.3.1 Generator Suppliers 
In the survey described above it was noted that 99mTc generators were supplied 
by three commercial providers: Mallinckrodt; IBA and GE Healthcare. Twenty-
eight different generator types and sizes were distributed from the different 
manufacturers. Generators are delivered on every day of the week except 
Sunday. The most common day for delivery was Wednesday (51%) followed by 
Saturday (42%) and Friday (24%) respectively.  Delivery of the generator on a 
Friday and Saturday results in decay of valuable product given that most 
departments do not undertake clinical work on a Saturday and Sunday. 
 
Analysis of the data returned in the survey showed that the use of customized 
software applications can provide a valuable means of optimizing weekly and 
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daily activity profiles and can increase the amount of radioactivity available on a 
daily basis whilst reducing costs. 
2.3.2 Generator Shortage Responses 
Nuclear medicine departments were asked if they had been affected by 
radioisotope shortages. The majority (93%) of nuclear medicine departments 
who responded had been affected by the shortages whereas 7% of departments 
claimed to have been unaffected. 
 
The survey also revealed the actions taken by nuclear medicine services during 
periods of supply shortages due to reactor outages. Those departments that 
were affected were asked to state how they had maintained services during 
times of generator shortage (Table 2.5). Seventeen percent of departments felt 
that the shortages had affected subsequent patient referrals. 
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Table 2.5 Responses to shortages of 99mTc-generators 
 
Response to generator shortages. % Number of 
respondents 
1 Postpone/reschedule patient 81.0% 85 
2 Use alternative radiopharmaceuticals 18.1% 19 
3 Send patients to other diagnostic 
modalities 
25.7% 27 
4 Reduce activity administered 48.6% 51 
5 Share activity with other units 30.5% 32 
6 Reduce or stop supplies to other units 9.5% 10 
7 Other (please specify) 32.4% 34 
 
2.3.3 Radiopharmacy Services Review Summary 
 The nuclear medicine community receives its generators from three 
commercial companies. 
 The majority of nuclear medicine services in the UK were affected by 
generator shortages. 
 Most nuclear medicine services in the UK have developed contingencies to 
deal with periods of shortage. In a small percentage of cases this change 
had affected future patient referrals. These include re-scheduling the 
patient, employing alternative radiopharmaceuticals, using lower tracer 
activities thus having an adverse impact on patient services. 
 There is evidence of loss of potentially useful radioactivity arising from the 
timing generator delivery schedules, which could be improved through 
better management. 
 The type, size, delivery and elution schedules for 99mTc generators are 
highly complex and software options exist to facilitate the correct choice 
and delivery of generators. 
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2.4 PET Radioisotopes UK 
 
18F-FDG PET-CT scanning is now accepted as a mainstream diagnostic test in 
most patients with lung cancer, lymphoma and colorectal carcinoma. The 
indications for PET-CT in the UK are varied and are set out in a joint document 
by the Royal College of Physicians and the Royal College of Radiologists 
document [4]. 
2.4.1 Demand for PET Services  
The current demand for PET-CT using 18F-FDG and other PET radioisotopes in 
the UK is uncertain. The 2010 BNMS Survey [1] estimated demand for PET-CT in 
the UK to be in the region of 20,000 investigations per year. However, for 
reasons previously stated, it is likely that this is an underestimate of the true 
demand; it is thought that the present number of PET-CT procedures currently 
undertaken in the UK is of the order of 40-50,000. Ninety percent of PET-CT 
procedures in the UK are performed using 18F-FDG for oncology indications; the 
remaining ten percent employ 18F-FDG for non-oncological indications or non-
18F-FDG PET radioisotopes for a variety of indications (oncological and non-
oncological). In line with global trends it is anticipated that the demand for PET-
CT in the UK will increase with time. The number of fixed site PET-CT Facilities 
in the UK has increased from 11 (6 in London) in 2005 to an estimated 34 (10 in 
London) in 2013 (Figure 2.3). In addition, under the existing national contract 
there are 40-50 PET-CT sites in England that are served by mobile PET-CT units. 
 
 
Figure 2.3 Fixed site PET-CT Facilities in the UK 2013  
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2.4.2 Supply of PET Radiotracers 
18F and other PET radioisotopes are generally manufactured using cyclotrons 
and do not require a similar complex supply chain to that for fission 99Mo, 
involving nuclear reactors, uranium-bearing targets or remote processors. 
Because of the short half-life of 18F (110 minutes), its derived 
radiopharmaceuticals such as FDG have to be manufactured close to where they 
are used; investigations using these ultra-short-lived PET tracers can only be 
carried out where there is co-location of the PET radiopharmacy facility and the 
hospital site. In contrast, a small number of radiopharmaceuticals such as 82Rb 
and 68Ga may be made available to hospital sites using generators (similar to 
those for 99Mo/99mTc). 
 
At present FDG is produced in cyclotrons distributed throughout the UK, some 
by commercial manufacturers and some by the NHS/universities. The present 
locations of the cyclotrons that are located in radiopharmaceutical production 
units (RPUs) are shown in Figure 2.4. 
 
 
 
Figure 2.4 UK PET cyclotrons (information derived from NCRI record of 
availability of cyclotrons in the UK [5]) 
 
The capacity of a PET radiopharmacy facility to manufacture FDG for PET 
scanning varies from one commercial manufacturer to another. This depends on 
a number of variables including cyclotron output capacity, number of clean 
rooms, number of synthesis boxes and dispensing units and the distance from 
PET centres served by the facility For a typical single-cyclotron PET 
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radiopharmacy operating 2 target irradiations per day (Monday to Friday) the 
distribution radius is typically within a travel time of approximately 2 hours 
(about one half-life). Any greater distance than that will impact on customers 
who are likely to suffer a shortfall of activity due to the physical decay occurring 
during the delivery period. 
 
Assuming a commercial site can deliver 20,000 patient doses of FDG per facility 
per annum, the potential number of doses of FDG that could be supplied from the 
6 operational commercial sites in England is in the region of 120,000; as can be 
seen from the map (Figure 2.4), there are some areas of the country where PET 
radiopharmacy facilities are under-represented. It would seem that at present 
there is sufficient capacity to meet demand there is sufficient capacity although it 
must appreciated there are times when FDG production fails and also times 
when facilities are out of action for service and repair. 
 
The Recommendations by ARSAC of the Impact of Recent Shortages of 
Molybdenum-99 and the Implications for Nuclear Medicine Services in the UK 
are set out in the Appendix 2.1 [6]. The response by the Department of Health to 
the ARSAC report is detailed in a 2012 report [7].  
 50 
Appendix 2.1: ARSAC Report 2010 
 
In response to the ongoing problem of shortages in the supply chain for 99Mo and 
99mTc, ARSAC undertook a review entitled ‘A Review of the Supply of 
Molybdenum-99, the Impact of Recent Shortages and the Implications for 
Nuclear Medicine Services in the UK’ [6]. The Report contained a number of 
recommendations as to how to mitigate the impact of periods of shortage of 
radiopharmaceuticals. 
 
Recommendation 1 
Nuclear medicine services are an integral part of healthcare and, despite the 
increased use of PET CT, for the near future, diagnostic nuclear medicine will 
continue to be based on 99mTc-labelled products. Security therefore of 99Mo 
supply is essential. This can be achieved in the long term at international level by 
investment to upgrade existing reactors and to build new research reactors, to 
ensure provision of 99Mo at a sufficient level to meet current and expanding 
demand during all foreseeable events. We recommend that the Department of 
Health and other government departments should continue to support European 
Commission initiatives to ensure a stable supply of 99Mo for Europe. In addition, 
the Commission and other international agencies should be supported in their 
efforts to amend European legislation to facilitate the transport of irradiated 
targets across national borders to ensure timely supply to generator 
manufacturers. 
 
Recommendation 2 
While the existing model for 99Mo production has proved effective for many 
years, the recent shortages have demonstrated that over-reliance on a few 
suppliers can prove problematic. We recommend that new technological 
solutions be monitored, including the potential long-term solution of UK-based 
production of 99mTc in medical cyclotrons. 
 
Recommendation 3 
Currently the three European companies that manufacture 99Mo generators do 
so during the working week rather than during weekends. This is not the case in 
the USA. We recommend that the Department of Health should explore with 
generator suppliers the feasibility of weekend production and alternative 
delivery schedules to ensure that 99mTc availability matches the traditional, 
efficient service delivery model for healthcare. 
 
Recommendation 4 
During periods of 99Mo shortages many hospitals have adapted traditional 
working practices, e.g. changing the radiopharmaceutical production model to 
provide a second elution and production run per day or working at weekends to 
make more efficient use of the available 99Mo. We recommend that where 
practicable hospitals should consider adopting some of these strategies on a 
permanent basis, and that traditional employment contracts should be amended 
to introduce flexible working patterns, to include weekends and extended days 
within the current pay constraints. 
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Recommendation 5 
Compared with Wales, Scotland and Northern Ireland, radiopharmaceutical 
production and supply within England are essentially local and are undertaken 
on a small scale. This is for historical rather than logistical reasons. While some 
larger central radiopharmacies exist, these are very much in the minority. The 
introduction of PET CT services in the UK using 18F-FDG has demonstrated that 
for routine diagnostic nuclear medicine services, a production and supply service 
based on fewer centralized facilities is viable. We recommend that the 
Department of Health undertake a review of radiopharmacy services to explore 
whether the number of large central radiopharmacies, which are more resilient 
during shortages, should be increased to provide the majority of 99mTc-based 
radiopharmaceuticals for safe and patient-focused nuclear medicine services 
within England. 
 
Recommendation 6 
Nuclear medicine imaging demonstrates functional information. It relies upon 
the administration of radiopharmaceuticals that in general are produced outside 
the UK. It has already been highlighted that 99Mo production using traditional 
technology is not practicable at UK level. PET-CT services, which can provide 
physiological information as an alternative to conventional nuclear medicine in 
some circumstances, rely upon local production of radiopharmaceuticals in 
cyclotrons. This is a robust supply chain; however, a large percentage of PET-CT 
services in England are currently provided through time-limited independent 
sector contracts. We recommend that adequate PET-CT services continue to be 
provided across the UK. Optimal coverage of these services should be ensured 
following the completion of the independent sector provision in England. 
 
Recommendation 7 
The UK has well-established regulatory frameworks designed to ensure the safe 
production, use and disposal of radioactive materials and radiopharmaceuticals. 
As a consequence of recent shortages, the Environment Agency in England and 
Wales has demonstrated a flexible approach regarding its own regulatory and 
enforcement policies to enable the most efficient use of available 99Mo while 
maintaining overall safety strategies. We recommend that the Department of 
Health, with other government departments and agencies, address options 
regarding transfer of radioactivity, radiopharmaceuticals and generators 
between different hospitals, with a view to issuing clear guidance. 
 
Recommendation 8 
Technological developments in gamma camera hardware and software design 
have the potential for nuclear medicine investigations to be performed using less 
activity. This has benefits for the patient with regard to radiation dose but also 
for the nuclear medicine service in terms of costs and efficient use of available 
99Mo. We recommend that a multi-centre, multivendor trial is undertaken in 
order that the viability of resolution recovery software with reduced activity is 
evaluated. If proved to be successful, we strongly recommend that nuclear 
medicine services purchase this software for new and existing gamma camera 
systems where applicable. 
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Chapter 3: Alternative Strategies for 
Imaging Diagnostics in the UK 
 
John Buscombe and Andrew Scarsbrook 
Summary 
 
 Most alternatives to 99mTc using radionuclides will be more expensive. 
 Some of the alternatives deliver much higher radiation doses.  
 Non-radionuclide alternatives may be available but may not be as accurate, 
may not be usable in all patients and would displace work on other imaging 
machines such as CT and MR which themselves may be limited. 
 Clinical studies would be required to evaluate objectively the relative 
benefits of alternative tracers for 99mTc as evidence is currently lacking. 
 A business case would be needed to estimate the current costs and 
availability of 18F Fluoride and 82Rb and how costs will change if they 
became the de facto standard. 
 Patients will be poorly served by not having a cheap, plentiful supply of 
99mTc.  
 For both imaging and therapy there is incomplete knowledge as to the 
numbers and types of procedures/therapies carried out in the UK. For 
strategic planning of services it is vital that this information is readily 
available. Where information is lacking this will have to be determined. 
 It will be necessary to investigate the potential of UK network development 
for the objective evaluation of new radiopharmaceuticals and cost/benefit 
analysis. 
3.1 Introduction 
 
Technetium-99m remains the main radionuclide used in nuclear medicine, the 
advantages being its ready availability via a generator and its gamma emission of 
140 keV that present gamma cameras are optimized for. It also has good 
dosimetric properties in that reasonable counts can be obtained by using 
administered amounts of activity generally less than 800MBq 99mTc. With the 
exception of myocardial perfusion scintigraphy, which uses two injections 
(stress and rest) the typical radiation doses of 2-4mSv similar to a single year’s 
exposure to background radiation in the UK. The cost of 99mTc agents is often 
reasonable especially if many patients are imaged from the same vial of 
radiopharmaceutical. 
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The use of 99mTc in nuclear medicine has evolved over the past 40 years and 
forms established diagnostic functional imaging techniques for a variety of 
medical complaints. 99mTc is most commonly used to investigate bone, cardiac, 
renal and pulmonary conditions. In recent years worldwide shortages in the 
production of 99Mo (the parent isotope of 99mTc) have intermittently affected the 
ability to perform these techniques. In November 2010 the Administration of 
Radioactive Substances Advisory Committee (ARSAC) report reviewed alternate 
imaging techniques using non-99mTc based nuclear medicine investigations 
(including PET-CT), CT, MRI and ultrasound [1]. At that point in time it was felt 
that due to a variety of factors including availability, manpower and additional 
cost that this would require substantial further investment in personnel and 
equipment to make it a robust and sustainable option. The eight 
recommendations of the ARSAC Report are set out in the appendix in Chapter 2 
[1]. 
 
There are often non-nuclear medicine tests available in these fields such as CT 
coronary angiography and echocardiography that may provide an alternative to 
gated myocardial perfusion imaging but may not provide all the information the 
clinician needs or may not be acceptable or useable in a particular patient. This 
means that despite the growth of other forms of imaging there remains a 
substantial practice using 99mTc-labeled products. 
3.2 Alternative Modalities 
 
In some circumstances it is possible to use a non-radionuclide procedure as an 
alternative, for example vital blue dye can be used for sentinel node localization 
but the failure rate can be much higher by about 10% compared to 5% with 
radiocolloids [1]. Emerging data also suggests that micro-bubble contrast-
enhanced ultrasound may provide a viable alternative to sentinel node 
lymphoscintigraphy in some settings [2]. 
 
Likewise it is readily accepted that MRI is a good method by which bone 
metastases can be detected and may be more sensitive than bone scintigraphy as 
it can identify the metastases directly whilst bone scintigraphy depends on a 
peri-metastatic sclerotic reaction. However, for many cancer types including the 
most common with bone metastases such as prostate and breast carcinoma it is 
important to cover the areas that metastases occur most commonly which is 
from skull to knees. 
 
To achieve this with an MR scanner this may take some considerable time - up to 
45 minutes per investigation. Capacity for additional MR scanning may be 
limited due to high demand and if MR was to replace the 10 bone scintigrams 
commonly performed daily in many nuclear medicine departments it would take 
a substantial portion of the MR capacity for that day. While this could be used on 
some occasions, if it was to become a permanent arrangement an additional MR 
scanner would be needed in most centers if other cases were not to be delayed. 
Also there is no guarantee the clinician who reads the bone scintigraphy is also 
trained in bone MRI so additional reporting manpower may be needed. 
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3.3 Use of Other Radionuclides 
 
It may be possible to replace 99mTc with other radionuclides (Table 3.1); for 
example either 123I or 131I imaging could replace 99mTc thyroid imaging. However, 
there are disadvantages with both of these radioisotopes. 131I is fairly cheap but 
has poor dosimetry. 123I has better dosimetry but is more expensive. Also the 
world supply of 123I may be limited with most production based in only two 
centres Eindhoven and Vancouver. 
3.3.1 18F-Sodium Fluoride (18F-NaF). 
18F-NaF provides an excellent alternative to bone scintigraphy [3] but has three 
disadvantages. As modern PET requires a co-acquired CT for purposes of 
attenuation correction the radiation dose of 18F-NaF is greater than bone 
scintigraphy. The cost of a study is presently almost three times greater than for 
bone scintigraphy. The third disadvantage is that it takes around 30 minutes to 
acquire the whole-body images required. Therefore to accommodate the 
required number of 18F-NaF bone scans the other work the PET scanner is doing 
would need to be done on a different machine. Free capacity on the available 
PET-CT scanners is likely to be limited in many parts of the UK. 
3.3.2 Rubidium-82 (82Rb) for Myocardial Perfusion Assessment 
A recent meta-analysis of 82Rb PET and SPECT myocardial perfusion imaging in 
the evaluation of obstructive coronary disease [4] revealed that 82Rb PET was 
more accurate (0.95 and 0.90 area under the receiver operating curve) than 
SPECT myocardial perfusion imaging. PET offers advantages over SPECT, 
including increased patient throughput because of rapid scanning protocols, 
reduced radiation exposure to patients and the ability to quantify tracer 
distribution accurately and myocardial perfusion reserve. Although 82Rb PET has 
advantages over SPECT, there are no large-scale prognostic or cost-effectiveness 
data to support its use as the primary MPS technique. Additionally, the 
availability of 82Rb PET is limited and at present restricted to only a few centres 
in the UK (principally at University College Hospital, London and at Manchester 
Royal Infirmary). A wider use of absolute measurements of perfusion has the 
potential to improve diagnostic accuracy and to add prognostic value over 
relative assessment of myocardial perfusion. 
3.3.3 Other PET Radiotracers for Imaging 
There are additional PET radiotracers that at present have limited availability 
and depend on access to local Cyclotron facilities. Certain of these tracers are in 
increasing clinical use while others are restricted and only available at a limited 
number of centres particularly those with research facilities. In summary: 
 
 A large number of potential agents using 18F are emerging [5], including 18F-
fluorothymidine (18FLT), 18F-fluoromisonidazole (18F-MISO), 18F-fluoro-
ethyl-tyrosine (18F-FET), 18F-fluorocholine (18F-Choline), 3,4-dihydroxy-6-
18F-fluoro-l-phenylalanine (18F-DOPA) and 18F-fluoroazomycin arabinoside 
(18F-FAZA). A limitation of 18F products, common to most PET radioisotopes 
is that it only has a 110-minute half-life and so cannot be sourced from 
outside the UK. 
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 There is a potential for the introduction of more 68Ga generators allowing 
on-site access to patients under investigation for neuro-endocrine 
malignancy [6]. 
 Other potential PET isotopes will become of increasing relevance, including 
124I (for thyroid and mIBG biokinetics), 89Zr (EGF, PSMA etc.), 64Cu 
(Hypoxia), 86Y (proven to predict therapy response from 90Y therapies and 
potentially useful to identify unnecessary therapy procedures). 
 
It should be noted that the UK lacks a large cyclotron such as the Arronax facility 
at Nantes in France and that could have implications for the development of 
novel Cyclotron-produced medical radioisotopes. 
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Table 3.1 Alternative tests for imaging studies 
 
Nuclear 
Medicine Study 
Cost 
£ 
Radiation 
mSv 
Alternative Test Cost      
£ 
Radiation 
mSv 
99mTc Bone Scan 280 3 Na18F 
MRI [7] 
800 
150 
9 
0 
99mTc 
Renography 
150 1 MRI [1] N/A  
99mTc-DMSA 
(Renal Scan) 
150 2  300  
99mTc Thyroid 100 1 123I/131I 300/80 4/8 
99mTc HIDA 
(Biliary Scan) 
150 3 MRI with 
Primovist [8] 
300 0 
99mTc 
Myocardial 
Perfusion Scan 
500 8 82Rb PET-CT[9] 
Cardiac Stress 
Echo [10] 
Cardiac MRI 
[10,11) 
500 
400 
900 
2 
0 
0 
99mTc White Cell 
Scan 
400 4 18F-FDG 
68Ga Citrate [12] 
900 
300 
4 
9 
99mTc MAA Lung 
Perfusion Scan 
150 2 CTPA[13] 
MRA 
68Ga-MAA [14] 
90 
300 
700 
4 
8 
? 
99mTc 
Parathyroid 
250 4 18F -DOPA 
Ultrasound [15] 
CT [16] 
11C-Methionine 
[17] 
4000 
40 
80 
1500 
? 
0 
? 
2 
99mTc Gut 
Transit 
150 0.5 MRI capsules [18]. N/A 0 
99mTc Sentinel 
node 
localisation 
150 0.1 Fluorescent dyes 
Microbubble 
Ultrasound 
N/A N/A 
N/A 
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Chapter 4: Non-Reactor Production of 
Technetium-99m 
 
Hywel Owen and Rob Clarke 
Summary 
 
This chapter summarises the technology options available for the non-reactor 
production of technetium-99m either directly or via its molybdenum-99 
precursor. Based on an assessment of the relative maturity of the different 
options and the possible co-use for purposes such as manufacture of other 
radioisotopes, it is concluded that the most promising technology for provision 
of 99mTc in the UK is its direct production using proton cyclotron bombardment 
at moderate energies between 18 and 24 MeV. 
4.1 Reactor Fission vs. Other Methods 
 
Whilst a variety of nuclear reactions are possible for the production of either 
99mTc, or more usually its precursor 99Mo, reactor-based fission of highly 
enriched uranium (HEU) targets remains the principle route by which 99mTc is 
obtained around the world today [1-7]. Nuclear reactors of moderate to high 
power (i.e. >1 MWth) provide a copious density of thermal neutrons; these 
initiate fissions in suitable HEU targets that are placed in the reactor, as they do 
in the rest of the 235U that makes up the fuel of the reactor itself; the withdrawal 
and rapid chemical processing (within days of irradiation) of the HEU targets 
means that the fission products with mass A=99 are predominantly molybdenum 
– i.e. 99Mo - and this chemical extraction allows the separation of the original 
target material (HEU) from the molybdenum product. Other (stable) 
molybdenum isotopes are also present in the separated product, but the end-of-
processing (EOP) specific activity is typically very high, around 3000 Ci/gm. 
 
The intrinsically-high specific activity, and the historical fact that these high 
bombarding fluxes were first obtained with reactors, has led to there being a 
mature development of the reactor fission approach at the expense of leaving 
alternative (non-reactor) approaches relatively under-developed. That said, 
there are intrinsic advantages associated with reactor fission 99Mo production 
compared to other methods; the advantages and disadvantages in general terms 
may be summarised as follows: 
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Reactor Fission 99Mo Advantages: 
Large flux of neutrons typically available 
Resulting fission 99Mo available in large quantities; single reactor provides large 
capacity 
 
Reactor Fission 99Mo Disadvantages: 
Larger capital cost cf. accelerator installations 
Licensing more difficult than most accelerator-based methods 
Significant waste stream compared to other methods 
Longer lead time for construction compared to other methods 
 
An important issue when choosing methods is whether the radioisotope 
produced is 99Mo – in which case a generator is utilised from which 99mTc is later 
eluted – or whether 99mTc is produced directly; whilst nuclear reactors have 
generally been used to produce 99Mo, accelerator-based methods may be used 
for either 99Mo or 99mTc. Direct production of 99mTc is chosen if the bombardment 
route produces 99Mo with a low specific activity, which is typical of 
transmutation reactions where the precursor is another isotope of molybdenum. 
The consequence of choosing either 99Mo or direct 99mTc production is that the 
latter method restricts the distance between production and usage due to the 
intrinsic difference in half-life between 99mTc (6 hours) and 99Mo precursor (66 
hours). The choice between these approaches thereby has a knock-on effect on 
the supply chain and infrastructure choices that are possible for the supply of a 
country or region. Loosely speaking, 99Mo may be produced in a different 
country from where it is used, whilst 99mTc most likely must be used within a few 
hours’ transport time from its site of production. 
4.2 Particles and Reactions 
 
Any chosen isotope may be manufactured by the bombardment of a suitable 
nuclide by an incident set of particles of appropriate energy; in this regard there 
is no particular difference between a nuclear reactor, a particle accelerator 
(whether conventional or laser-based) or any other method, other than what 
technology is able to produce the particles required. As such, a variety of 
reactions are possible both in reactors and in particle accelerators that may 
transmute a (typically) stable parent nuclide into either 99Mo or into 99mTc. 
These reactions broadly fall into one of two groups: fission-based methods, and 
transmutation-based methods; the most prominent reactions are discussed 
below, followed by a discussion of how the accelerators providing for the 
bombardment may be provided. 
 
An important distinction between fission and transmutation routes is that whilst 
fission-based approaches will naturally produce a large specific activity product 
they must inevitably involve the use of uranium-containing targets. Neutron-
based fission approaches in practice require the use of 235U as the target nuclei 
due to the much lower fission cross-section of 238U, and so highly enriched 
uranium (HEU) targets may be required. However, HEU targets (defined as 
>20% enrichment, but usually much higher) minimise the waste stream volume 
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for a given amount of molybdenum product, but they raise proliferation 
concerns and must therefore be managed carefully; the long-term aim of the USA 
RERTR programme [8], augmented by the American Medical Radioisotopes 
Production Act 2012, is to eliminate the civilian use of HEU either in reactor fuel 
assemblies or in targets, and to replace them with the use of LEU targets with 
enrichments of 20% or lower [6,7,9]. Whilst the proliferation concerns of LEU 
targets are reduced, the intrinsic presence of 238U atoms in the target plates gives 
rise both to an increased waste stream (around four times as much as when HEU 
targets are used, for a given amount of molybdenum product), and also gives rise 
to the generation of plutonium. Whilst these two issues are tractable, they are 
less suitable compared to other methods to be adopted for local production, for 
example at a hospital or industrial setting such as is done with cyclotron-based 
18F production. These processing and waste issues are of relevance to any non-
reactor methods that would utilise uranium targets, the most notable being 
photofission. Overall, whilst photofission may utilize LEU or depleted uranium 
targets, the waste stream and processing issues may give rise to licensing issues 
and processing complications similar to using a nuclear reactor, hence reducing 
the capital advantage of using an accelerator. 
4.2.1 Neutron-Induced Fission 
Neutron-based fission of 235U atoms has already been described above, wherein 
reactor neutrons which typically have thermal energies (~1/40 eV) are able to 
induce fission in 235U atoms but not in the 238U atoms which have higher natural 
abundance in uranium ore; this gives rise to the need for enriched targets. In 
principle 233U- or 239Pu-containing targets could also be used for 99Mo 
production, but these are impractical due to their (non)availability, their having 
similar or greater proliferation concerns cf. 235U, and far more difficult handling 
and processing. For example, it has been proposed to utilize a 233U-based molten-
salt reactor (i.e. with liquid rather than solid fuel) and to conduct online fission-
product extraction to obtain 99Mo [10,11]. However, this technology is immature 
compared to the established irradiation of solid HEU targets in light-water-
cooled research reactors. 
 
Whilst fast neutrons (~1 MeV) may be used to induce fission in 238U (or even in 
transuranic nuclides), this is impractical in reactor systems due to the much 
greater complexity involved in the required fast reactor technology. However, 
fast neutrons are available in reasonably large fluxes using either low-energy 
nuclear reactions (for example c. mA currents of protons or deuterons incident 
on Li, Be, or C targets, as used for boron neutron capture therapy [12] or for 
neutron irradiation of materials for fusion reactor studies [13,14,15]), or high-
energy spallation-based reactions such as protons on Pb targets [16,17]. There is 
a trade-off: neutron production using low-energy protons gives low yield but a 
high current is possible; spallation gives more neutrons per proton but requires 
a larger accelerator that can obtain a relatively lower current. Lower-energy 
reactions used for neutron production vary from the 2.8 MeV threshold energy 
for the Li(p,n) reaction on solid or liquid targets [12,16,18], through to the 
c.40 MeV deuteron energies proposed for hard neutron production on the 
proposed IMFIF and FAFNIR irradiation facilities [13,14]. Spallation reactions 
such as p on Pb benefit from the much higher neutron multiplicity available at 
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proton bombardment energies above around 600 MeV, and a broad optimum for 
accelerator cost and current exists for proton energies around 1000 MeV, at 
which energy around 20-30 neutrons are produced per proton dependent on the 
target material and geometry; solid Pb, W and U and liquid Hg targets have all 
been utilised [13,14,15,16,17]. 
 
Both the low-energy and spallation methods have been proposed as methods for 
99Mo production. Three examples are notable. The first is the proposed use of 
low-energy D-T neutron generators surrounded by either a depleted uranium 
(238U) assembly or a subcritical assembly or subcritical uranium-containing 
solution. The c.100 kV D-T ‘neutron generator’ is now a widespread source that 
may be bought in a variety of geometrical configurations from a number of 
suppliers: whilst originally developed as neutron triggers for nuclear weapons, 
these generators are now most often used for pulsed neutron generation whose 
use for example is in oil well diagnostic imaging [19]. The accelerated species is 
ionised deuterium gas, whilst the tritium is present as a sputtered scandium 
hydride target on a copper target backing. Apart from the naturally low capture 
yield in the subcritical assembly (unless the neutron reproduction k value is 
brought close to k=1, leading to a system rather similar to a proper reactor from 
the point of view of licensing), two deficiencies of D-T approach are the low 
typical lifetime for the neutron generators, and the care required to avoid tritium 
leakage. The second approach is the proposal to use spallation neutrons from 
either a high-power neutron source - such as ISIS (Oxfordshire) [20] or the 
European Spallation Source (to be constructed in Sweden) [21] - or from a high-
power linac for particle physics such as the CERN Linac 4 [22] or the Fermilab 
Project X proposal [23], where a similar spallation target would also be used. The 
final scheme is to utilize a medium-energy proton cyclotron (100 MeV to 
350 MeV), such that each proton (impinging on a robust high-Z target such as 
tungsten or tantalum) produces a few neutrons per proton which then pass into 
a subcritical assembly; the subcritical assembly will contain 235U either in solid 
or solution form, the latter most often proposed as an aqueous solution. For 
example, the IBA ADONIS scheme proposes a 150 MeV, 2 mA proton cyclotron 
and a subcritical (k<0.9) assembly incorporating HEU targets and a combination 
of Be and heavy water moderator material to tailor the spallated neutron energy 
to values optimal for fission [24]. 
 
A different way to generate neutrons for fission is to utilize a two-stage 
combination wherein (e.g.) Bremsstrahlung in a tungsten target is used to 
generate c.15 MeV gamma rays from a high-current (c.20 to 100 mA) beam of 
electrons of energy around 50 MeV [25,26]. The Bremsstrahlung gamma rays can 
then be converted in the same target - or in another one - to produce 
photoneutrons using a (,n) photonuclear reaction [27]. Those outgoing 
neutrons then impinge onto a uranium target or subcritical assembly containing 
uranium. The low photonuclear cross-section is offset in part by the fact that it is 
much easier to generate very high currents of electrons than it is to generate 
high currents of protons; several technologies - including superconducting linacs 
[28,29] and rhodotrons [30,31] – are available that can in principle allow very 
large electron currents, and the initial gamma-producing target is typically 
where the power limitations will occur in practical designs. 
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A closely-related method to the photonuclear fission scheme is to utilize the 
Bremsstrahlung photons directly to initiate photofission in a uranium target, 
where the photofission cross section also peaks at gamma-ray energies around 
15 MeV [32]; however, unlike neutron-initiated fission, photofission may be 
produced in both 235U and in 238U, although the 238U photofission cross section at 
such neutron energies (170 mbarn) is rather lower than for 235U (400 mbarn) 
[27]. Both cross sections are much lower than the thermal neutron fission cross-
section (600 barn), and so again much greater fluences of photons are required 
than neutrons for the same fission rate; but again, the lower cross-section is 
compensated for by the fact that the intermediate photonuclear conversion stage 
is not needed. This latter scheme has been proposed and developed by SHINE 
Medical Technologies in partnership with LANL, and uses a 100 mA deuteron 
current at 300 keV to generate around 1014 neutrons per second from a gas 
target, the neutrons are moderated with a Be multiplier before impinging on an 
aqueous solution of either LEU uranium nitrate of sulphate; estimated 
production is up to 500 6-day Ci per week of 99Mo as well as other isotopes [32]. 
IBA have proposed a separate scheme using their rhodotron electron accelerator 
technology, which proposes a subcritical homogenous liquid target of LEU salts 
in heavy water and which utilises a HDPE reflector [33,34]; limiting the electron 
beam power to 450 kW – which is already very high - implies that a k-value very 
near to 1 (i.e. k=0.99) is needed, which has implications with regard to nuclear 
licensing. If a lower production rate is acceptable then a depleted 238U target may 
be utilised directly (and in which k<<1); this scheme is similar to that utilised in 
several radioactive ion beam (RIB) nuclear physics facilities, but differs in 
whether the fission products escape from the target. The TRIUMF photofission 
proposal was originally recommended by a Canadian review of non-accelerator 
production as the best route for 99Mo production [28], and which was considered 
as a beam current upgrade (to 100 mA) of the proposed 10 mA ARIEL RIB 
facility. 
 
It may be seen that a number of neutron/fission schemes are possible. However, 
they are limited by one of three factors depending on the particular scheme: 
 The need for very high proton currents at low energies, and the power 
limitation on the low-energy target; 
 The need for moderate currents and a large capital cost/size for a 
spallation-based approach, which restricts this sort of scheme to regional-
based production; 
 The need for both very high electron currents and subcritical assemblies in 
the photonuclear/photofission approaches, the latter of which makes 
nuclear licensing more difficult. 
The principal advantage of all the non-reactor fission-based methods is that the 
resulting product will be sufficiently similar that it may be substituted for 
reactor fission 99Mo. 
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4.2.2 Neutron Capture 
Neutrons have also been used to generate 99Mo using neutron capture in 98Mo 
targets, which targets are typically enriched to prevent the co-production of 
other molybdenum isotopes [4,6,7,28,35]. Reactor-based methods such as 
implemented recently at MURR are limited both by the available flux and that in 
most reactors the neutron spectrum is rather thermalised, which limits the 
resultant saturation specific activity to several Ci/gm; nevertheless, generator 
technologies such as that used by NorthStar are able to produce suitable 99mTc 
product by this route, and potentially from other transmutation reactions giving 
low specific activity. The harder spectrum available in some reactors may be 
used to achieve an enhancement of the capture rate through capture of neutrons 
in the epithermal resonances of the 98Mo nucleus, and this has been proposed by 
several groups, notably in patents by Carlo Rubbia that outline the use of a liquid 
target [36,37,38]. However, the broad, mostly thermalised, spectrum means that 
the saturation activity is at best only increased a few times [39]. 
 
The spectrum of neutrons available from an accelerator target - whether 
spallation or otherwise - is typically much harder than that available from a 
reactor, and with appropriate shaping (using a tailored moderator) can be used 
to enhance the rate of neutron capture in a nuclide's resonance region. This 
resonance neutron capture technique was originally proposed as a method of 
enhancing the rate of neutron capture in 99Tc and other long-lived fission 
product nuclear waste, by a number of researchers including Carlo Rubbia 
[40,41]. A number of accelerator and target (both solid and liquid) 
configurations have been proposed for the production not only of 99Mo, and 
several have been implemented [42,43]; for example, the company Advanced 
Accelerator Applications s.a. (AAA) in France currently utilize a 30 MeV proton 
linac and Be neutron-producing target coupled to a lead moderator, which is 
used for the generation of niche isotopes such as 154Ho using resonant capture 
[37]. However, it is inherently difficult to shape a neutron spectrum using 
scattering-based moderators, so that the practical enhancement in capture rate 
even in accelerator-based methods is probably limited to less than a factor of 
100. 
 
As well as the developed AAA facility in France, several other proposals are of 
note. CERN have proposed the utilisation of a high-power proton spallation 
target located on Linac 4 to carry out neutron capture for 99Mo production [44]. 
Whilst the possible capacity of such a production facility would be quite large, 
the large capital, infrastructure and expertise requirements to construct and 
operate such a facility means that it could only be done nationally (and perhaps 
only internationally) and not locally. That said, such a facility could in principle 
be located either at a national accelerator facility such as one of the STFC sites 
(Rutherford Appleton or Daresbury), or at a nuclear-based site. Another option 
would be to locate such a target at a spallation source such as ISIS or ESS, similar 
to the possibilities for a fission-based approach; some discussions have been had 
in the past about the use of both facilities for isotope production, but at present 
there are no firm plans. 
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A locally-based facility would require a compact, high-current proton source: one 
model for this is use of compact neutron sources developed for boron-neutron 
capture therapy (BNCT), such as the 2.8 MeV DC proton accelerator used at 
Birmingham to generate neutrons from a solid Li target [18]. Similar to other 
neutron facilities utilising low-energy accelerators, Li, Be or C targets may be 
used; beam powers greater than around 3 kW require the use of flowing liquid Li 
rather than solid Li targets [12]. Designs have been developed for applications 
such as BNCT and materials irradiation; one such example is the proposed 
40 MeV FAFNIR deuteron linac to be used for materials studies for the ITER 
fusion project [13,14]. Co-location of a neutron capture target on such an 
irradiation facility, or duplication of the linac and target design on a separate 
facility, are both in principle possible. 
 
Neutron capture methods have the advantage that there is no use of uranium 
targets or fission product processing. The disadvantages are the inherently low 
specific activity; there is no practical method for separating 99Mo from the 
original 98Mo target material, and so either a low-activity generator or direct 
dissolution of the target would be needed. 
4.2.3 Photonuclear Transmutation 
As well as photofission, gamma-ray production from a high-intensity electron 
accelerator may be used to conduct photonuclear transmutation of a 
molybdenum target; in this case, the reaction of interest is 100Mo(,n)99Mo 
[6,7,35]. Similar to neutron capture, either solid or liquid Mo-containing targets 
may be used, but the conventional geometry utilises a set of thin Bremsstrahlung 
converter targets (typically tantalum or tungsten) followed by one or more solid 
(enriched) 100Mo targets. The energy required from the high-current (10 mA or 
greater) electron beam must be enough to deliver a significant number of gamma 
rays around the c.15 MeV giant dipole resonance energy, which for practical 
purposes means an electron energy of 35 MeV or more. Hence the source and 
target technology is essentially the same as that for photofission production. 
 
Whilst electron bombardment has an intrinsically lower cross-section, this is 
countered by the fact that electron accelerators of high current capability are 
generally simpler, more reliable, and able to deliver higher currents than proton 
accelerators for similar purposes. A side-benefit is that photons are also more 
penetrating, allowing for the use of windows and thicker targets. Provided a 
reaction channel exists for the desired isotope, the generally fewer reaction 
channels available result in an inherently reduced production of undesired 
isotopes and therefore waste compared to fission. 
 
Several proof-of-concept photonuclear production facilities have been 
constructed. One such is the Canadian NRC-INMS prototype at Ottawa, which has 
used a 35 MeV, 2 kW electron linac to irradiate 2 cm diameter enriched 100Mo 
targets using a water-cooled tungsten Bremsstrahlung converter target; 
automated direct extraction of technetium from the dissoluted irradiated targets 
(Na2MoO4 solution) has been demonstrated in a partnership with NorthStar 
technologies. The Canadian Light Source have since constructed a 20 MeV, 20 kW 
industrial electron linac to carry out the same irradiation using a stacked target 
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with a likely 48-hour bombardment time 45]. Dissolved targets are then shipped 
as Na2MoO4 solution from which 99mTc is extracted in an automated separator 
such as that form NorthStar. Production rates are said to be able to scale to 
around 2 TBq/day, and the PIPE/NorthStar consortium is proposing a network 
of up to 16 linacs to supply 50% of US requirements [46]. 
4.2.4 Proton-Induced Transmutation 
Transmutation caused by proton bombardment of a metal target was one of the 
earliest methods of using an accelerator to create radioactive species; indeed, 
Emilio Segre first identified the artificial element technetium in 1937 following 
the parasitic deuteron bombardment of a molybdenum deflector plate in the 
Lawrence 37-inch cyclotron. Subsequent to this a considerable number of 
measurements were made following Beaver and Hupf’s 1971 proposal to 
manufacture significant quantities of 99mTc using proton cyclotrons [47,48]. 
Latterly, Tom Ruth’s group at TRIUMF revived this idea [49] which was then 
developed by both that lab and at the University of Alberta. Work by Katie 
Gagnon and others have shown both theoretically and experimentally that an 
enriched 100Mo target is required to avoid unwanted side reactions (see later 
chapters of this report) [50,51,52,53,54,55,56,57,58,59,60]. In this regard, 
proton irradiation of an enriched 100Mo solid target is much the same as for 
photonuclear irradiation, except that the target plate used for proton irradiation 
is much thinner (see below). The processing of these targets will be rather 
similar to each other and to the processing of 98Mo targets used for the neutron 
activation method. 
 
The TRIUMF and University of Alberta approaches are similar, but differ in 
certain respects. In both cases it is recognized that an incident proton energy of 
at least 19 MeV is required to obtain a good trade-off between radionuclidic 
purity and yield. For example, at TRIUMF a 100Mo target thickness of around 
300 m (on a tungsten backing plate) is used to tailor the exit proton energy to 
remain above 10 MeV. 19 MeV has been adopted in experimental bombardments 
to understand how existing 19 MeV PET-producing cyclotrons might be adapted 
for technetium production. To that end, test targets have been produced both for 
GE PET-TRACE cyclotrons (e.g. the 880) and ACSI TR-19 cyclotrons. In either 
case, thermal power is managed by tilting the angle of incidence of the beam on 
target; this is more easily done in the TR-19 target arrangement, which has 
subsequently been adapted by University of Alberta for use on TR-24 cyclotrons, 
and where they have adopted an aluminium backing plate. A higher-energy 
cyclotron will produce greater yield of product and also some commercial 
cyclotrons are available at these energies with currents approaching or even 
exceeding 1 mA. At higher currents dual extraction ports are likely to be typical, 
in which a carbon foil is adjusted at each port to determine the current extracted 
to each target. One model might be to run extraction ports alternately in 
different shielded areas, so that activation issues can be managed by moving 
irradiations to the other port if required. Some cyclotron designs allow then for 
dual operation (via extraction line switching dipoles) so that more than one 
target station (and therefore type) may receive protons from an extraction port. 
This would allow for bombardment to manufacture – for example - 18F on one 
target, and then 99mTc on another target. 
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Much progress has been made in the last several years in developing suitable 
targetry and chemistry for proton bombardment [55,60,61]. Enriched 100Mo 
feedstock material is available at around USD 500 per gram at present, and it is 
thought this cost may decrease if it is more widely used. Historical sources 
derived from stable isotope centrifuge enrichment have mostly been used to date 
– principally of Russian origin - but these are now being augmented by freshly 
enriched 100Mo where it is possible tailor the relative composition of the other 
stable isotopes. This will assist in reducing the co-production of unwanted Tc 
isotopes as detailed later in this report, and thereby will assist in controlling the 
extra patient dose from these isotopes. 
 
Target plates developed at the two Canadian sites mentioned typically utilise 
around 80 mg or so of 100Mo which is then sintered and pressed into the backing 
plate. Initially it was thought that efficient recycling of the feedstock material 
was needed due to the high cost, and hence attention was given to achieving 
good recycling during 99mTc extraction; rates greater than 90% have now been 
demonstrated at TRIUMF. However, there remain issues about ensuring isotopic 
consistency of target batches if recycled material is used and how this might 
affect both actual patient doses and how such targets might be licensed. One 
model might be to have a national or even international single site where target 
recycling may be done such that isotopic consistency can be assured. However, if 
100Mo feedstock price falls significantly then it may not even be necessary to 
recycle it. 
 
Experimental irradiation work on cyclotron-produced technetium to date is 
promising. Experimental yields now approach prior theoretical estimates, for 
example that a 200 uA, 19 MeV cyclotron can produce around 0.4 TBq of 99mTc in 
a single 6-hour bombardment; discussion remains about whether a single 6-hour 
or two 3-hour bombardments are best. Also, some testing will be needed of 
target irradiations at high cyclotron currents to examine the durability, but it is 
likely that currents exceeding 500 uA will be feasible. 
 
Scaling the present production estimates, it is estimated that two 19 MeV, c.300-
500 uA cyclotrons could produce around 1 TBq of 99mTc per day in a single 
bombardment each; this would be sufficient for the UK population demand of 
around 600,000 doses per year, but does not account for any downtime of the 
cyclotrons themselves [35]. 
4.2.5 Summary 
We assess that cyclotron-produced technetium is at present the most mature 
technology available relevant for UK needs, based on several considerations. 
Firstly, the accelerator and targetry are effectively developed, and production is 
now being achieved at scales relevant to volume production. Secondly, 
understanding of how to control radionuclidic purity is better demonstrated 
with this method than with others. Thirdly, the possible co-use of such facilities 
to produce other isotopes such as 18F is attractive when considering overall 
capital cost. Finally, such cyclotrons and associated processing lend themselves 
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more easily to licensing and local hospital use. We next consider the various 
accelerator technologies available. 
4.3 Particle Source Technologies 
4.3.1 Electron Accelerators 
Electron linacs of up to several tens of MeV and several tens of kW of output 
power are available industrially, and are already used for a variety of irradiation 
applications such as cable sheath processing and sterilization. Most linac designs 
in industrial use are based on conventional 3 GHz radio-frequency structures, 
and the power and current limitation arises principally from limitations in 
structure heating and water cooling. Very high power electron linac designs over 
10 mA, particularly for higher-energy applications above 50 MeV output, have 
looked to superconducting accelerating structures to limit the resistive heating 
in the cavity walls. Significant progress has been made in this area over the last 
twenty years, with both US (1.5 GHz) and European (1.3 GHz, so-called ‘TESLA’ 
type) designs capable in principle of delivering 100 mA of continuous beam 
current. For example, TRIUMF have previously proposed an upgrade to their 
Ariel photofission linac to obtain currents of 100 mA at 50 MeV for photofission 
production [28]. 
 
An alternative to linear accelerators is to use the commercial-only Rhodotron 
method, in which electrons are accelerated across the diameter of a cylindrical 
accelerating cavity [30,31]. After each crossing a magnet ‘petal’ returns the 
electron beam back to the same common cavity and with the correct phase for 
further acceleration, a process limited by the magnetic fields available in the 
petals; electron beam powers in excess of 200 kW are now available, with the 
final electron energy from a single Rhodotron being around 10 MeV. Whilst the 
number of crossings per Rhodotron is limited by geometry and power 
availability, it has been proposed to have a sequence of such accelerators where 
the output from one feeds to the next. Both IBA and AMIC have proposed such a 
scheme in which Rhodotrons supply electrons to a subcritical assembly for 
fission molybdenum production, but in principle such accelerators could also be 
used for photonuclear production. 
4.3.2 Low-Energy Proton Accelerators 
Low-energy protons may be characterized as those which may be supplied by 
commercial accelerators. The vast majority of these accelerator sources are 
conventional proton or deuteron cyclotrons (i.e. that involve the use of a single 
magnet with static dipole field) operating with energies up to around 30/15 MeV 
(p/d) [62,63,64]. The primary market for these cyclotrons is for the production 
of short-lived isotopes such as 18F for PET, but they may also be used for other 
isotope production by changing the target assembly. Typical proton currents 
obtained over the 15-30 MeV (relevant for 99mTc production) range from 30 to 
1500 uA, and at higher currents power handling becomes an issue both in the 
beam extraction (if used) and in the isotope production target. A number of 
manufacturers offer cyclotrons in this energy and current range, nearly all of 
which utilize normal-conducting electromagnetic dipoles. A typical example of a 
compact cyclotron is the IBA Cyclone 18/9 (p/d), which utilises a 1.35 T magnet 
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and which weighs 25 tons (c.2 m diameter and 2.2 m height), delivering around 
150 uA of proton current to up to 8 target ports. Very high current cyclotrons 
will typically accelerator negative hydrogen ions so that beam extraction can be 
efficiently obtained to enable the highest currents. The primary current limit is 
in the target extraction foil which is typically arranged as a carousel wherein one 
of a number of carbon foils are presented into the beam to strip the electrons 
from the circulating H- ions and thereby extract them. One such design is the 
ACSI TR-24 used at the University of Alberta for 99mTc production where two 
extraction ports are provided, and in which the relative currents extracted are 
determined by how far each foil is presented into the circulating beam. Stated 
lifetimes of foils are said to be several weeks. The very highest currents are 
achieved using extraction of H- ions; hence such cyclotrons cannot be of the ‘self-
shielded’ variety and must utilise a conventional shielded bunker within which 
the cyclotron and targets are situated. 
 
In the last few years attention has been given to the design of more compact 
cyclotrons which operate at lower energy. The reasoning is that the increased 
current and decreased size available at lower extraction energy offset the 
decreased isotope yield of for example 18F, with the argument that the smaller 
size of cyclotron enables more compact hospital-based radiopharmacies. As 
discussed above, the requirement for proton energies up to 24 MeV means that 
compact cyclotrons are less straightforward for direct 99mTc production. 
 
A method of reducing the cyclotron size is to utilize superconducting magnet 
technology, and several groups have developed this. The AMIT project, which 
includes the Spanish CIEMAT institute, is developing a 4 T, 8 MeV self-shielded 
proton cyclotron for 18F and 11C production using an internal target [65]. At 2 
tons the weight is much reduced compared to higher-energy cyclotrons, and a 
little lower than comparable low-energy cyclotrons that utilize normal-
conducting magnets such as designs from ABT Molecular (3 tons) and OSCAR 
(3.5 tons). Ionetix have recently demonstrated a cryo-cooled 12.5 MeV proton 
cyclotron using 6 T NbTi superconductor to allow the entire cyclotron to fit 
within a cryostat, and which operates using dewar LHe and 35 kW of wallplug 
power to manufacture 13N [66,67]. 
 
Although the use of either superconducting technology or lower energy may 
reduce the size and weight of the cyclotron magnets, it does not eliminate their 
use entirely. One approach to eliminate the need for magnets is to utilize DC 
acceleration, i.e. with a Van de Graaf or equivalent DC accelerator. Historically 
these have needed to be rather large (many meters in length) to hold off any 
significant voltage (1 MV or greater), and so have been restricted to being used 
for heavy ion acceleration. Tandem acceleration may be used to double the 
effective voltage, in which a negative ion accelerates across a DC voltage, is 
stripped of electrons by passage through a foil, and then re-accelerated through 
the same potential difference. Tandem pelletrons are now available 
commercially that can accelerate a variety of ion species to reasonable energies; 
for example, the now-operating Dalton Cumbrian Facility will eventually obtain 
up to 100 uA of protons up to 10 MeV [68,69]. The practical limit for voltage has 
been around 10 MV (20 MV tandem), for example at the now-decommissioned 
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Daresbury Nuclear Structure Facility. Recent innovations in semiconductor 
technology have allowed the development of a novel geometry called the Oniac 
[70]. Siemens and the STFC Rutherford Appleton Laboratory (RAL) have 
collaborated to demonstrate this accelerator, in which the DC stack is in the form 
of a set of concentric shells with the high voltage and stripper foil at the centre; 
no magnetic fields are thought to be required, reducing the weight and cost of 
the accelerator, but with a similar limit on available voltage. The overall size of a 
10 MV accelerator is estimated to be around 1 m in diameter, and tests are 
proceeding at RAL at which so far a few shells have been tested up to perhaps 
1 MeV. 
 
Another approach to obtain medium-energy protons is to use conventional 
proton linacs, and whilst a number of configurations are possible a notable 
example is the Front-End Test Stand (FETS) at RAL [71]. Although designed as a 
front-end for a future high-power (> 5 MW) spallation source, the FETS injector 
has so far demonstrated 6 mA of average (H-) current at 65 keV; at present this is 
delivered with a pulsed time structure (around 10% duty factor) that may not be 
compatible with isotope target irradiation, but this may perhaps be changed. 
FETS is due to complete the addition of a 324 MHz radio-frequency quadrupole 
(RFQ) to deliver 3 MeV protons [72]. A later addition of linac structures could 
provide a very intense beam of H- ions that could in principle be utilised for 
isotope production. However, it must be pointed out that whilst the proposed 
current from FETS is somewhat higher than from present cyclotrons, it has not 
yet been demonstrated nor a cost comparison been carried out. Given the 
complexity of the design it is not clear if either the capital cost or operation of a 
linac would be favourable, and indeed the cyclotron was originally invented as a 
method of alleviating the complexities of linacs when obtaining moderate-energy 
protons. 
 
A final approach to obtaining moderate-energy protons is to adapt the design of 
compact cyclotrons to obtain a low-energy FFAG (fixed-field, alternating-
gradient) accelerator. These may be thought of as cyclotrons with stronger 
focusing, and one such design led by University of Huddersfield proposes four 
separate magnets and an internal target for 99mTc production [73]. At present 
this is a theoretical study, and a comparison of advantages and disadvantages 
compared to operating cyclotrons has not yet been presented in the literature. 
4.3.3 High-Energy Protons 
High-energy proton production has mostly aimed at provision of either rather 
low currents at very high energies (many GeV) for uses in particle colliders for 
particle physics, or at lower energies (around 1 GeV) at higher currents for use in 
applications such as spallation neutron production for scientific use, neutron 
generation for accelerator-driven subcritical reactors, or a variety of neutrino- or 
muon-based experiments that require a high intensity beam of protons as a 
generating source. At the lower c.1 GeV energies the present limitation in current 
is the continuous beam power of c.1 MW that is delivered by the Paul Scherrer 
Institute 590 MeV cyclotron, which delivers an effectively continuous beam 
current up to 2.2 mA [74,75]. This current has been achieved after some years of 
 72 
study and development, and such machines are generally reserved for use by 
accelerator laboratories with the manpower to develop and support them. 
 
In contrast to cyclotrons, spallation sources used for neutron scattering typically 
deliver pulsed bunches of protons, and thereby neutrons for users; the pulsed 
neutron production is required to enable various experimental techniques 
valued in condensed matter physics, such as neutron diffraction. The main two 
existing spallation sources  - ISIS in the UK (160 kW) [21] and the SNS in the USA 
(1.1 MW) [76] - are based around a linac pre-injector followed by a synchrotron, 
but the next-generation 5 MW European Spallation Source utilises a linac-only 
design as the user-required pulse structure is different [77]. With appropriate 
beamline components it is in principle possible to extract a small fraction of the 
beam current for other purposes, and this is already done on ISIS for muon 
production using a thin carbon target upstream of the main tungsten spallation 
target. Spallation sources are very large installations costing ~£1 billion, and so 
are only trans-national projects. Their use for isotope production must take into 
consideration the complexities of extracting a portion of the beam, the reliability 
of the facility, and the lack of facility redundancy in the case of equipment failure. 
 
It should be noted that large cyclotrons delivering powers in excess of 1 MW are 
also in development. For example, the DAEDALUS neutrino project proposes an 
800 MeV superconducting H2+ cyclotron to deliver around 10 MW of continuous 
beam power [75,78], but whilst ion source and cyclotron magnet development 
are becoming mature the demonstration of an integrated design remains some 
years away. 
 
Whilst both linacs and cyclotrons are in principle capable of extremely high 
beam power, both these large-scale machines are complex and therefore difficult 
to operate, and are probably not appropriate to consider in the context of 
radioisotope production. That said, isotope production has been proposed at 
both the CERN Linac 4 project [44] and for the Argonne National Laboratory 
Project X proton accelerator. 
 
At lower energies more conventional accelerator designs become accessible. A 
reference point are the cyclotrons developed for proton therapy; these are 
limited in practice to proton energies up to around 250 MeV, and have 
demonstrated currents up to around 0.5 to 1 uA that are sufficient for delivery of 
therapeutic beams [79,80]. Several of the manufacturers of these cyclotrons have 
proposed higher-current, lower-energy cyclotrons for isotope production. For 
example, IBA have proposed a 150 MeV, 2 mA cyclotron for spallation neutron 
production either for subcritical reactor studies or for 99mTc production (see 
below) [6,81]. As yet no demonstration of these cyclotron parameters has been 
made. 
4.3.4 Neutron Production 
Neutron production may be performed using a variety of methods. As indicated 
earlier, production methods are generally either low-energy nuclear reactions 
such as 7Li(p,n)7Be [12], or spallation reactions in high-Z targets carried out 
most efficiently using c.1 GeV protons. At low energy the neutron multiplicity 
 73 
(neutrons per proton) is rather poor: a typical example is the existing 2.8 MeV 
Birmingham dynamitron which presently delivers around 1 mA (3 kW) of 
protons onto a solid lithium target [18]. Power is limited by the available cooling 
of the target, and significantly higher powers almost certainly require the use of 
liquid targets, for example as at the Israeli SARAF facility [12,82]. Most of the 
energy given to the protons during their accelerator is simply lost again through 
ionization slowing, and this is a feature of all low-energy production methods. At 
somewhat higher energies the neutron production cross section in beryllium 
targets becomes favourable, and is utilised for example by AAA for neutron 
capture isotope production (see above). A novel recirculation method through a 
thin target becomes possible at higher proton energies; this method – called 
ERIT (energy recovery internal target) [83] - utilises an FFAG accelerator with 
large beam acceptance to cope with the transverse scattering induced by each 
proton passage through a Be foil target with a thickness of a few microns [73]. 
The use of a sufficiently thin target, plus re-acceleration and recirculation after 
each pass, allows the re-use of the vast majority of protons that did not produce 
neutrons on prior passes, whilst at the same time optimizing the energy of the 
proton as it passes through the target to maximize the neutron production cross 
section. This method is already in practical use at KURRI in Japan to produce 
neutrons for boron neutron capture therapy (BNCT) [83], and has been 
considered for neutron production for both isotope production and security 
scanning [73]. A similar target concept might be used directly for 99mTc 
production in which the Be foil were replaced by a 100Mo foil. However, given the 
heat load suffered by more robust carbon foils in conventional cyclotrons, it is 
likely that using this method for 99mTc production will present formidable 
difficulties. 
 
At higher energies, and with higher-Z targets, spallation starts to dominate 
neutron production, and the neutron multiplicity rises above 1 neutron per 
proton for incident proton energies above c. 150 MeV [16,17]. Although the 
multiplicity in large targets continues to rise with proton energy, consideration 
of the accelerator and energy cost for accelerating each proton results in an 
optimum incident proton energy around 1 GeV, although this peak in incident 
energy is quite broad; a 1 GeV proton incident on a lead target will produce 20-
30 neutrons depending on the target size and shape; the size of target is 
determined by the requirement to make best use of the inter-nuclear cascade of 
produced protons and neutrons generated from the initially-struck target 
nucleus. As evidenced in the design considerations for the European Spallation 
Source (ESS), a variety of solid and liquid targets have been considered, 
including solid uranium (previously used at ISIS), solid tungsten/tantalum (used 
at ISIS), liquid mercury (used at SNS), liquid lead (used at Paul Scherrer 
Institute) and liquid lead-bismuth eutectic (studied for the MYRRHA reactor). As 
well as the demonstrated solid and liquid targets used at ISIS and SNS for 
neutron scattering, PSI have already demonstrated around 1.2 MW beam power 
on a liquid lead target in the context of accelerator-driven subcritical reactor 
development. Liquid targets help both to overcome the beam power (melting) 
limitations of solid targets and to cope with the shock and ablation caused by the 
incident proton beam pulses. Other methods which have been considered 
include the use of powder jet targets, and rotating solid targets to assist in power 
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dissipation; the ESS project has adopted the latter of these in its baseline design 
that is currently under construction in Sweden [84]. 
4.3.5 Laser Acceleration 
As discussed above, the direct production of 99mTc from 100Mo targets 
bombarded by moderate-energy (18-24 MeV) protons is the most promising as 
an alternate technology to reactor fission. However, conventional accelerators 
are not the only choice; laser-based accelerators may utilise the same 100Mo 
target, extraction mechanisms and recovery cycle as that proposed for cyclotrons 
and other conventional accelerators. Since the early 2000s there has been a great 
deal of research on the acceleration of high-energy protons using one of several 
laser-plasma based acceleration mechanisms [85,86,87,88]. This work has in the 
majority been directed towards providing suitable beam properties for hadron 
therapy where proton energies up to around 250 MeV with narrow energy 
spread (c. 1 MeV) are desired [79,80]. The work in this field has seen progressive 
increases in achieved energy and fluence is now approaching the above 
specifications [88,89,90,91,92]; it is predicted that, with sufficient power, 
protons up to several GeV energy might be obtained. 
 
Several groups have also performed experiments to investigate the production of 
radioisotopes, concentrating initially on the production of PET isotopes such as 
18F and 11C [93,94,95]. This research has utilised the existing broadband proton 
output which has been achieved to generate radioisotopes through (p,n) 
reactions typically using the giant resonance peaks: 11B(p,n)11C and 18O(p,n)18F. 
The most notable technique at present is target normal sheath acceleration 
(TNSA), which phenomenon dominates ion production at laser intensities of 
1019-1021W/cm2, and which uses thin (few um) foil targets. Single-shot 
production of 10s MBq of 11C and 100s kBq 18F were demonstrated in 2004 [94]. 
More recently, investigations into direct 99mTc production using the same 
mechanism has yielded 8 kBq [96] of 99mTc from natural molybdenum targets in 
each laser shot, which would to ~90 kBq if an enriched (99.54%) 100Mo target 
were used. Each laser shot comprises typically a ~1 ps laser pulse of between 
50-200 J focused onto a single target which (though multiple mechanisms) 
accelerates the protons; TNSA gives a broad output proton energy spread from 
which the giant resonance peak results in around one 99mTc nucleus for 1000 
protons (18-24MeV). To generate clinically-relevant yields the laser repetition 
rate must be increased above present sub-hertz values; it is estimated that pulse 
energies of c.50 J at repetition rates over 10 Hz would yield a 1 GBq patient dose 
in a 20-minute irradiation using current laser and targetry designs. 
 
Presently, given the overall efficiency, size and cost of such a laser system, there 
is no particular advantage over a cyclotron, as the latter is able to produce 
around a factor of 100 greater yields over the same exposure time. To be 
competitive the laser method would have to be around 1/100th of the cyclotron 
cost. Over a 10-15 year timescale this might be possible; the introduction of 
diode-pumped pulsed lasers has increased laser efficiency dramatically and 
significantly reduced thermal loads. This has enabled laser systems to increase 
repetition rates from a few shots per hour towards 10 Hz in only a few years; 
given the role of such laser systems in research and industry significantly, the 
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achievement of significantly higher repetition rates seems possible. So whilst not 
competitive at present, laser acceleration of protons may become a practical 
alternative in around 10 years. 
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Chapter 5: Radiochemical, 
Pharmaceutical, Dosimetric, and 
Operational Considerations for Cyclotron 
Produced 99mTc:  
Jim Ballinger and Louise Fraser 
Summary 
 
 International efforts have demonstrated that production of 99mTc by 
cyclotron is a feasible technology, though it requires infrastructure and 
incurs ongoing costs of daily production and transport. 
 It has been demonstrated on a small scale that standard 99mTc based 
radiopharmaceuticals can be prepared using cyclotron produced 99mTc and 
that their chemical and biological properties appear unchanged. 
 There is an increased radiation dose associated with the co-produced 
longer-lived radionuclides of Tc.  There may be other regulatory issues 
related to the licensing of kits and acceptable levels of radiochemical 
impurities. 
 Provision of 99mTc based radiopharmaceuticals across the UK using 99mTc 
produced in a small number of cyclotrons will likely involve a combination 
of central and local radiopharmacies in order to optimize service provision.  
There should be public sector oversight of this process. 
 Workforce issues and training shortages both within radiopharmacy and to 
the wider nuclear medicine community in the UK cannot be underestimated 
– a full impact assessment must be undertaken as part of any move away 
from the traditional supply chain for 99mTc radiopharmaceuticals. 
5.1 Good Manufacturing Practice (GMP) Compliant Processing 
of Target Material 
 
This chapter starts at the point when a 100Mo target is removed from a cyclotron 
vault.  As this will almost certainly be a solid target system it involves a physical 
transfer process.    The subsequent steps are: 
 Dissolution of the target 
 Recovery of 100Mo 
 Purification of 99mTc 
Dissolution of the metal target under oxidizing conditions, such as using H2O2, 
yields molybdate and pertechnetate in solution.  It is not practical to separate the 
two using standard generator technology (i.e. aluminium oxide column) due to 
the large quantity of Mo present, which would require an excessively large 
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column in order to achieve adequate separation [1, 2].  Solvent extraction with 
butanone (methyl ethyl ketone) has been used in some parts of the world for 
many years, but is difficult to perform safely and efficiently on the scale required 
[3]. Sublimation has also been evaluated and offers the advantage of recovery of 
99mTc in a small volume of saline [4].  However, anion exchange column 
chromatography would appear to be the most promising approach, as it is 
relatively straightforward to automate [1, 5]. 
 
In one such process [1], the target is dissolved in H2O2 and passed through an 
anion exchange cartridge.  The 100Mo is washed through using 3 M ammonium 
carbonate and collected.  The cartridge is washed with 1 M sodium carbonate 
and the eluate taken to waste.  Finally 99mTc is eluted with distilled water 
through a cation exchange cartridge into the collection vial.   
 
An automated device has been designed at TRIUMF in Vancouver [5].  The 
irradiated 100Mo target (80 mg) is dissolved in 10 mL H2O2 at 60oC and filtered 
through a polyethylene frit before being mixed with 20 mL 5 N KOH.  The 
solution is passed through a 500 mg ABEC-2000 (aqueous biphasic extraction 
chromatography) column and washed with 3 mL 3 N KOH, with the waste going 
to the 100Mo collection bottle.  Flow rates up to 5 mL/min do not affect trapping 
or recovery.  99mTc is then eluted with 5 mL distilled water and the solution is 
neutralized by passage through a strong cation exchange cartridge.  The eluted 
99mTc is trapped on an alumina cartridge and washed off with saline.  The 
isolation efficiency was 84% in less than 30 minutes. The extent of recovery and 
recycling of 100Mo is critical to the economics of the project.  The consistency of 
purity of recycled 100Mo is also critical as it affects the profile of radionuclidic 
impurities produced, discussed below in the dosimetry section. 
5.2 Specifications for Cyclotron-Produced 99mTc 
 
The current pharmacopoeial specifications are as follows. The European 
Pharmacopoeia (Ph. Eur), harmonised with the British Pharmacopoeia (BP), has 
different specifications for radionuclidic purity depending on the method of 
production of 99Mo.  The Ph. Eur has begun deliberations on specifications for 
cyclotron produced 99mTc and intends to have a draft by early 2015.  The current 
United States Pharmacopoeia (USP) specifications are presented for comparison 
(Table 5.1). 
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Table 5.1: Specifications for Cyclotron-Produced 99mTc 
 
 
  
Parameter BP/Ph. Eur USP 
Appearance Clear, colourless 
solution 
Not stated 
Tonicity In normal saline In normal saline 
pH 4.0 to 8.0 4.5 to 7.5 
Aluminium <5 ppm <10 ppm 
Sterility Sterile Sterile 
Endotoxins <175/V EU/mL <175/V EU/mL 
Radionuclidic purity 
– fission 
131I <0.005% 
99Mo <0.1% 
103Ru <0.005% 
89Sr <0.00006% 
90Sr <0.000006% 
Other gammas <0.01% 
Alphas <10-7% 
131I <0.005% 
99Mo <0.015% 
103Ru <0.005% 
89Sr <0.00006% 
90Sr <0.000006% 
Other gammas <0.01% 
Alphas <0.001 Bq/MBq 
Radionuclidic purity 
– non fission 
99Mo <0.1% 99Mo <0.15 kBq/MBq (0.015%) 
Other gammas <0.5 kBq/MBq 
(0.05%) 
Max 92 kBq/dose 
Radiochemical purity >95% TcO4 >95% TcO4 
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A number of papers (Table 5.2) have included evaluation of their results against 
the USP specifications: 
 
Table 5.2: Comparison of published results against USP specifications 
 
Parameter USP Spec Gagnon [1], 
new target 
(n=4) 
Gagnon [1], 
recycled 
target (n=3) 
Morley 
[5] 
Galea 
[6] 
pH 4.5 to 7.5 5.0 to 7.0 6.0 to 6.5 5.5 6-7 
Radiochemical 
purity 
>95% TcO4 >99% >99% - 97-99% 
Aluminium 
content 
<10 ppm <2.5 <2.5 <5 <10 
Radiochemical 
identity 
Rf 0.9 - - 0.9 - 
Molybdenum 
content 
Not specified - - <5 ppm - 
99Mo content <0.015% - - <0.001% <0.015% 
 
Results for radionuclidic purity will be discussed below in the dosimetry section.  
In summary, it appears that all of the current pharmacopoeial specifications can 
be met except for radionuclidic purity.  A detailed theoretical and experimental 
assessment by Lebeda et al [7] predicts a best case of 0.06% contribution from 
Tc radioisotopes other than 99mTc, principally 95Tc (t½ 20 h) and 96Tc (t½ 4 d). 
 
It must also be remembered that the radionuclidic purity decreases with time 
after production, since longer-lived radiocontaminants contribute more as the 
primary radionuclide decays.  The limits are set for the time of use (or expiry) of 
the 99mTc solution.  This could be a problem if the irradiation ends at, say, 04:00 
but the last injection is planned for 16:00, by which time the radiocontaminants 
could have increased 4-fold.  This is considered by Hou et al [8]. 
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5.3 Preparation of 99mTc Labelled Products 
 
Once the 99mTc pertechnetate has been purified, a range of 99mTc products would 
be prepared from kits.  Although there are some concerns that problems may 
arise, the available information suggests that current kits perform satisfactorily 
with cyclotron-produced 99mTc, at least on the scale studied so far. 
 
The main concern is with specific activity due to the presence of larger amounts 
of 99Tc than is seen with generator 99mTc and also other radioisotopes of Tc.  This 
increases the total chemical quantity of Tc present in the labelling solution, 
which may affect: 
 The ability of the stannous ion in the kit to reduce 99mTc to the correct 
oxidation state 
 The stability of the resultant 99mTc complex as there will be less excess 
ligand present; this could mean a shorter shelf life, which could be a 
problem for supply from central radiopharmacies 
 
As discussed recently by Qaim et al [9] the specific activity of cyclotron-produced 
99mTc starts out roughly equivalent to “Monday pertechnetate”, with which there 
are recognized problems of the nature mentioned above.  With decay of 99mTc 
during the day the situation becomes even more unfavourable for preparation of 
kits at later times.  There is also a theoretical concern that this lower specific 
activity product could have subtly different biodistribution properties. The 
following table (Table 5.3) summarises the published results on products 
prepared using cyclotron-produced 99mTc: 
  
 85 
Table 5.3 Published results of products prepared using Cyclotron-produced 
99mTc 
 
Reference Product Cyclotron 99mTc results Comparison 
Radiochemical studies 
Gagnon [1] MDP 97% 99% generator 
Nagai [4] MDP >99% Meets USP spec 
Richards 
[10] 
MDP >99% Meets spec 
Galea [6] MDP 93-97% 94% 
Tetrofosmin 96-97% 97% 
Jalilian [11] Sestamibi 94±3% Meets spec 
DTPA 98±1% Meets spec 
DMSA 97±2% Meets spec 
Phytate 96±2% Meets spec 
Benard [12] Sestamibi 99±1% Meets spec 
MDP 98±3% Meets spec 
HMPAO 91% Meets spec 
Pre-clinical studies 
Gagnon [1] MDP Normal rabbit bone scan Similar to generator product 
Galea [6] MDP Bone uptake = 114 
Bone/liver = 2.95 
Bone uptake = 109 
Bone/liver = 2.75 
Tetrofosmin Similar myocardial 
accumulation and retention; 
Heart/liver = 2.5 
Heart/liver = 2.5 
Richards 
[10] 
MDP Normal mouse bone scan Expected biodistribution 
Jalilian [11] Sestamibi Heart, kidney, and GI tract 
highest 
Expected biodistribution 
DTPA Kidney and bladder highest Expected biodistribution 
DMSA Kidney and bladder highest Expected biodistribution 
Phytate Liver and spleen highest Expected biodistribution 
Clinical studies 
McEwan 
[13] 
Pertechnetate Normal biodistribution No difference between 
cyclotron and generator 
Selivanova 
[14] 
Pertechnetate Normal biodistribution No difference between 
cyclotron and generator 
 
As pointed out by Qaim et al [9], in the validations performed so far the kits may 
not have been “stressed” with maximum activities nor worst-case specifications 
of cyclotron produced 99mTc (e.g. long irradiations, higher level of co-produced 
Tc isotopes).  In recent years, the regulatory authorities have imposed 
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restrictions on the use of eluates of generators which have not been eluted for 
more than 24 h (i.e. “Monday pertechnetate”), which could have implications for 
the acceptability of cyclotron produced 99mTc. 
 
It is also of concern that there is still no published clinical evaluation of 
cyclotron-produced 99mTc, only an abstract in 2012 from the Edmonton group 
[13] and another in 2014 from the Sherbrooke group [14], both using 
pertechnetate. 
5.4 Dosimetry Considerations When Using 99mTc Produced by 
a Cyclotron 
 
There are three potential routes that can be used to produce 99mTc using a 
Mo(p,x)X reaction: 
 
1) 98Mo(p,)99mTc 
2) 100Mo(p,2n)99mTc 
3) 100Mo(p,pn)99Mo -> 99mTc 
 
Impurities in cyclotron-produced 99mTc have implications for 
radiopharmaceutical chemistry and patient dosimetry. These impurities include 
a large number of various radioactive and stable isotopes of technetium, 
molybdenum, niobium and zirconium.  
 
In contrast, 99mTc produced from a reactor-produced 99Mo generator is 'pure' in 
that it only contains 99mTc and its decay product 99gTc, though it can contain up to 
0.1% 99Mo breakthrough and much lower levels of other radionuclides. 
 
There is a need to optimise the cyclotron operational parameters to maximise 
the production of 99mTc and to minimise contaminants. These parameters 
include: 
 Beam energy 
 Irradiation time 
 Target enrichment 
 Cooling time (time after end of beam) 
 
Non-technetium impurities (including Mo, Nb, Zr) can be removed via chemical 
separation provided this is performed correctly and efficiently. These impurities 
will constitute radioactive waste and become potential sources of contamination 
from the cyclotron production lab. Chemical separation cannot isolate 99mTc from 
the remaining technetium isotopes, so the radiopharmaceutical preparations will 
contain these impurities and will increase the patient radiation dose. The 
radioactive technetium isotopes are shown in Table 5.4 (those isotopes 
produced with T½ >103 years are considered stable): 
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Table 5.4 Half-lives of Important Technetium Isotopes. 
 
Isotope Half life 
99mTc 6.01 h 
97mTc 91.4 d 
96mTc 51.5 min 
96gTc 4.28 d 
95mTc 61 d 
95gTc 20 h 
94mTc 52 min 
94gTc 293 min 
93mTc 43.5 min 
93gTc 2.75 h 
 
Hou et al [8] have produced theoretical dosimetry data for three commonly used 
radiopharmaceuticals: sestamibi, phosphonates and pertechnetate. They also 
investigated the effect of target composition, beam energy, irradiation and 
cooling time on patient dosimetry estimates. These theoretical dose estimates 
were compared to those from 99mTc obtained from a 99Mo generator. The 
calculations from Hou et al demonstrate that the target enrichment must be 
carefully considered. The percentage of 100Mo enrichment must be high but the 
relative amounts of other Mo isotopes, particularly 95Mo, 96Mo and 97Mo, should 
be minimised to reduce the production of 95gTc and 96gTc which contribute 
significantly to patient dose.  
 
Hou et al [8] suggest that the most favourable proton energy for cyclotron-
produced 99mTc would be in the region of 16-19 MeV. At higher proton energies, 
the production of other technetium isotopes increases and these impurities 
contribute considerably to patient dose.  
 
In addition, Hou et al [8] suggest short irradiation times and cooling times less 
than 12 hours. Using a 6 h irradiation time, a target enriched to 97.39% 100Mo, 
proton energy through target from 19-10 MeV, and a cooling time of 2 h, the 
percentage increase in patient effective dose is 0.69, 0.54 and 0.63% for 
sestamibi, phosphonates and pertechnetate respectively. Selivanova et al 
recently estimated similarly low increases in effective dose with optimal 
irradiation times, target enrichment values, and beam energies [14]. 
 
These theoretical calculations need to be verified by direct experimental 
measurement. Lebeda et al [15] have recently reported on radiochemical purity 
quality control measurements on a range of radiopharmaceutical kits 
manufactured using cyclotron-produced 99mTc. Their results showed no 
impurities in seven out of the nine kits tested. These results are promising, but 
direct comparison to 99Mo-produced 99mTc was not performed and no 
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measurements were made at a later time, where a contribution from longer-lived 
technetium isotopes may be demonstrated. Further work is still required in this 
area. 
5.5 Feasibility and Commercial Analysis 
 
The OECD Nuclear Energy Agency report of 2010 predicts that a 6 h irradiation 
in a suitable high-power cyclotron could yield >1 TBq of 99mTc, enough to supply 
a population of about ~10 million people [16].  Lebeda claims to have produced 
1.8 TBq (unpublished).  The TRIUMF group recently demonstrated that 350 GBq 
99mTc can be obtained following 7 h irradiation at 18 MeV and 220 μA [12]. 
 
An economic analysis of cyclotron 99mTc costs would have to include the 
following: 
 Capital costs: cyclotron, laboratories, targetry, purification equipment 
 Consumables: targets, reagents, testing 
 Personnel: numbers and grades; unsocial hours payment 
 Transport: from central production sites 
 
A big question is whether 99mTc production could be piggy-backed onto existing 
current 18F (PET) production in a single facility. In terms of timing, this should be 
possible, as a 99mTc production run might be 22:00 to 04:00 followed by 
processing, during which time the 18F bombardment could take place.  In terms 
of capital costs this might make sense, provided that there is access for transfer 
of the solid target and sufficient space for the 99mTc purification process to take 
place.  However, there is increased risk of impact on the PET production if there 
are problems with the cyclotron or facilities.  There is also concern about 
“flogging” the cyclotron, with additional wear and tear caused by continuous 
running.  Dual operation with other isotopes also limits 99mTc production to one 
(overnight) run per day, and makes a second bombardment for 99mTc 
problematic. 
 
It is emerging that it might be better to plan two runs per day.  As discussed in 
section 5.3, one of the factors that result in increased levels of radionuclidic 
impurities is prolonged irradiation times.  Prolonged irradiation periods may be 
required in order to achieve an adequate yield of 99mTc, particularly if the 
cyclotron beam current is low [17].  This would likely require a dedicated 
cyclotron, which would increase the capital cost. In any case, there would need to 
be back-up supply from a nearby unit for the inevitable downtime due to 
equipment failures. 
 
An economic analysis has been obtained from the Edmonton 
Radiopharmaceutical Centre, where a 24 MeV cyclotron has been installed solely 
for 99mTc production.  The parameters in the model include: 
 Capital cost of purchase and installation, amortized over 20 years; 
 Operating costs; 
 Staffing; 
 Consumables; 
 89 
 Regulatory; 
 Maintenance. 
The bottom line is that operation at a level of 200,000 doses per year would 
result in an average cost of Canadian $20 per dose (equivalent to £10.80) for the 
pertechnetate component.  A recent survey of UK radiopharmacies indicated an 
average crude cost for pertechnetate of £8.54 per dose, with unit dose at £7.66 
and multidose at £10.32.  Thus, the cost of cyclotron-produced 99mTc is quite 
comparable to current generator prices, and would become even more 
competitive as generator prices increase due to anticipated full economic costing 
of reactor-derived 99mTc. 
 
There are two cyclotrons explicitly marketed for 99mTc production, and another 
that has been proposed for adaptation for 99mTc. These are summarised in Table 
5.5. Other cyclotron manufacturers are likely to market the potential of their 
products to manufacture 99mTc, and/or offer integrated solutions. 
 
Table 5.5 Notable Cyclotron Manufacturers relevant to 99mTc production 
 
Manufacturer Model Energy (MeV) Beam current 
(μA) 
Advanced 
Cyclotron Systems 
Inc. 
TR24 18-24 300-1000 
Best Cyclotron 
Systems Inc. 
B15p 
B25p 
15 
20 or 25 
400 
400 
GE Medical 
Systems 
PET trace 880 
Upgrade 
Future 
16.5 130 
250 
400 
5.6 Radiopharmaceutical Preparation Using Cyclotron-
Produced 99mTc 
 
At first glance, it would seem to be most efficient for the bulk 99mTc to be used for 
preparation of kit-based products at a single location adjacent to the production 
site, rather than being sent in batches to a number of smaller radiopharmacies.  
Here the model of large North American radiopharmacies could be studied in 
order to make best use of the available 99mTc. 
 
However, centralized radiopharmaceutical preparation might not be possible if 
the stability of the products, and hence the shelf life after labelling, were 
insufficient for efficient clinical use after transport.  It could be that a 
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combination of central and local preparation is required for optimal quality of 
products, efficiency of use, and flexibility of provision of clinical service. 
 
This was discussed more thoroughly in the 2010 ARSAC report [18].  Among the 
potential problems to be considered are the following: 
 
 Greater impact of equipment failure at central radiopharmacy.  If there is 
no local back up, a failure in the air-handling unit would affect a large 
number of hospitals. Microbiological contamination or a radiation spill 
within the radiopharmacy could have a similar effect. Recovery times 
could be of the order of 1-2 weeks. 
 Reliance on a daily supply of active starting material.  Daily supply of bulk 
99mTc rather than generators that can be used over a period of up to three 
weeks means that there is no back-up supply should the cyclotron fail. A 
large number of hospitals would be affected. The recovery time would be 
dependent on the nature of the problem with the cyclotron. 
 Fewer alternatives for back-up supply. This is less catastrophic than the 
unit failure mentioned above, but could include shortages of staff, a 
particular product or occasional failure of a 99Mo generator. 
 Access to technical procedures.  Services that require direct 
radiopharmacy involvement as part of the procedure (e.g. gastric 
emptying, blood labelling or denatured red cells) may be limited at 
remote sites due to the unavailability of trained staff and a lack of 
specialised facilities. However, arrangements can be made for provision 
of some of these services, such as sending trained staff to remote sites or 
transporting blood to the radiopharmacy for radiolabelling. 
 Access to professional services.  Services that require senior staff 
involvement for patient facing roles (e.g. patient counselling, therapeutic 
administration, medicines history taking and medicines interaction 
reviews) may not be provided as the employment of senior staff solely for 
this purpose would not be financially justifiable. 
 Critical dependence upon transport.  Transport introduces a source of 
uncertainty due to traffic conditions and reliance upon the availability of 
trained drivers and equipped vehicles.  The logistics of supplying ~200 
nuclear medicine departments daily from a very small number of central 
locations are seen as challenging. 
 Delays in obtaining extra doses.  The transport time will have to be taken 
into account when extra or urgent doses are required. This may not be 
possible for all sites. 
 Limitations on weekend supply.  Individual hospitals would have to 
negotiate with the central radiopharmacy for weekend or extended hours’ 
supply. 
 High extremity radiation doses to radiopharmacy staff.  This could be 
reduced by introduction of automation that may be economically feasible 
in a smaller number of specialist centres. 
 Reduced quality of life for central radiopharmacy staff.  Due to early start – 
this could lead to problems in recruitment and retention of staff. 
 Loss of scientific role of radiopharmaceutical scientist. As provision 
becomes primarily a technical service, although this would probably be 
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more of a problem in the commercial sector. Within the NHS the scientific 
role would remain, but only if large radiopharmacies were located within 
clinical and research environments [19]. 
 Workforce issues  Multi-professional training in radiopharmacy practice of 
allied professional groups in nuclear medicine (e.g. physicists, clinicians, 
radiologists, radiographers, clinical practitioners and technologists) could 
not be accommodated in larger units where rationalisation has occurred 
because of the higher throughput pressures and the increased demand as 
a result of fewer numbers of units. 
 Learning and development within radiopharmacy The Modernising 
Pharmacy Careers Board has proposed in a report to Health Education 
England that there should be national workforce planning for the 
specialist pharmaceutical technical areas [20]. As a result, the Clinical 
Pharmaceutical Scientist Training programme was established. 
Radiopharmacy training is an integral part of this training programme, 
and on completion, graduates are able to work in all technical areas of 
pharmacy. A reduction in capacity for education and training would affect 
this training programme as well as other training schemes which require 
radiopharmacy input. 
 Lack of professional leadership  Reduction in the headcount of senior 
professional staff in radiopharmaceutical services will diminish both 
radiopharmacy and nuclear medicine services for the reasons besides 
affecting a technical supply: 
o Lack of professional leadership 
o Loss of corporate memory 
o Lack of innovation 
o Loss of service development 
o Reduced cross-sector audit 
 Loss of radiopharmaceutical expertise in the wider community  Although 
consultant radiopharmaceutical scientists would be available in the 
central radiopharmacy there would be less access to local expertise for 
advice on clinical issues and research. This can also be a limitation for 
training programmes in nuclear medicine technology, medical physics, 
and specialist medical registrars in nuclear medicine and radiology. 
 
If the independent sector takes the initiative to develop cyclotron based 
production of 99mTc, there should be an impact assessment held by the public 
sector on the current model of radiopharmacy services and the knock on effect to 
nuclear medicine (both diagnostic and therapeutic) prior to any development 
taking place. BNMS and the UKRG are best placed to do this. 
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Chapter 6: Radionuclides for Therapy and 
Imaging (Theragnostics) 
Glenn Flux and Adrian Hall 
Summary 
 
 There is currently no record in the UK of the numbers of treatments 
delivered with radiotherapeutics, the number of centres offering 
treatment, or of the details or outcome of the treatments themselves. Only 
two surveys have been held to obtain a snapshot of current activity. 
 Radiotherapeutics are particularly prone to shortages, as these cannot be 
stockpiled due to the natural decay of the radioisotopes and the limited 
time for stability of radiolabelling. Many radiotherapeutics are produced 
at single sites that may be outside Europe. Supplies can be halted at short 
notice, preventing completion of a course of treatment. There is no 
evidence or protocol governing continuation of treatment. 
 In many cases, two or more radiotherapeutics are available for 
treatments. In the absence of head-to-head clinical trials, the treatment of 
choice at any given centre is dependent on local logistics and clinical 
judgement rather than on evidence 
 The costs of radiotherapeutic drugs for cancer treatment is estimated to 
have increased from £2.5m - £8m from 2007 – 2012 and is projected to 
increase to ~ £50m in the coming years, dependent on NICE approval of 
commercial products. 
 MRT is a highly multi-disciplinary field. Resource costs and the workforce 
required to deliver radiotherapeutic treatments effectively and safely 
have not to date been estimated. These will rise in line with the drug 
costs. 
 The EU directive 2013/59, mandating dosimetry-based treatment 
planning for MRT as for external beam radiotherapy and brachytherapy, 
will have a significant impact on treatment procedures and on resource 
issues. 
 Treatment protocols are currently standardised only where these have 
been formulated by the company providing the radiopharmaceuticals, 
following commercially funded clinical trials. A limited number of 
academically driven trials have been conducted, although these are 
difficult to fund and perform. Support for academic development would 
ensure UK competitiveness, a national supply and rapid translation of the 
drug into clinical practice.  
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6.1 Introduction: 
 
Many radionuclides (radiotherapeutics) used for molecular radiotherapy (MRT) 
of cancer and benign disease also act as ‘companion diagnostics’ that permit 
functional medical imaging. This allows staging and treatment planning prior to 
therapeutic procedures and response monitoring following therapy. The 
potential to directly image the agent responsible for treatment is unique to MRT 
and is a leading example of the emerging field of ‘theragnostics’. 
Radiotherapeutics are also vulnerable to reactor, processor or distribution 
failures that can disrupt not just diagnostic information from scanning but the 
treatments themselves.  
 
At present, there is no national registry for the treatment of cancer with 
radiotherapeutics and consequently no record of the treatments administered, 
the centres offering treatment, or of outcome data. The figures given below of UK 
usage are taken from a BIR report [1] that followed a survey in 2007, and a 
recent survey conducted by the UK Internal Dosimetry Users Group [2]. 
6.2 Current Practices 
There are numerous options for treatments using beta-emitting radioisotopes, 
although currently there are 5 main treatments: 
6.2.1 Thyroid Cancer and Benign Thyroid Disease 
Iodine-131 [131I]) has been used extensively in the treatment of benign thyroid 
disease, for thyroid remnant ablation following surgery for thyroid cancer and 
for the treatment of thyroid metastases in differentiated thyroid cancer for over 
60 years. This remains the treatment of choice for the majority of diagnosed 
cases. A recent survey from the UK Internal Dosimetry Users Group [2] found 
that ablation procedures following surgery increased by 33% over the years 
2007 – 2011. 
6.2.2 Adult Neuroendocrine Tumours 
Refractory adult neuroectodermal tumours, such as phaeochromocytoma and 
paraganglioma, are routinely treated with Yttrium-90 (90Y) or Lutetium-177 
(177Lu) radiolabelled peptides, referred to as Peptide Receptor Radionuclide 
Therapy (PRRT), or with 131I-mIBG in at least 11 centres in the UK (an increase 
from only four centres in 2007). For the period 2007 – 2011 the number of 
treatments with radiopeptides increased by 173%. 
6.2.3 Paediatric Neuroblastma 
131I-mIBG is also used to treat primary refractory and relapsed neuroblastoma in 
children in three centres in the UK. Two of these centres are in London. 
6.2.4 Palliation of Bone Metastases 
Samarium-153 (153Sm) EDTMP, Strontium-89 (89Sr) and Rhenium-186 (186Re) 
HEDP are used to palliate pain due to skeletal metastases in patients with 
prostate cancer. In 2013 the alpha-emitter Radium-223 (223Ra) Dichloride was 
approved by the FDA for the treatment of patients with castration resistant 
prostate cancer (CRPC), symptomatic bone metastases and no known visceral 
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metastatic disease, following clinical trials that demonstrated improved survival 
and symptom control in comparison with a placebo [3].  
6.2.5 Microsphere Treatments of Liver Cancer and Liver Metastases 
In recent years, two commercial products have emerged for the treatment of 
liver tumours with 90Y microspheres. Both products use a similar administration 
technique whereby the radioactive spheres are directly injected into the hepatic 
artery. The microspheres differ only in terms of the size, composition and 
activity concentration of the spheres themselves. This new treatment modality 
has expanded rapidly (from 23 treatments in the UK in 2007 to 155 treatments 
in 2011). These products are currently undergoing commissioning through 
evaluation. 
6.2.6 Additional Therapies 
Further treatments are performed on an ad hoc basis in various centres in the 
UK. These include 90Y Zevalin for non-Hodgkin’s lymphoma, P-32 for the 
treatment of craniopharyngioma in children and 90Y labelled anti-CD66 for 
haematopoietic stem cell transplantation.  
6.3 UK Stakeholders 
In recent years a number of groups have emerged to deal with one or more 
aspects of this highly multi-disciplinary field. These include: 
 
IDUG (Internal Dosimetry Users Group). Primarily concerned with internal 
dosimetry for molecular radiotherapy. 
 
CERT (CRUK/ECMC UK Radiopharmacy Task Force) – Focussed on the 
translation of new academic radiotherapeutics into clinical practice. 
 
CTRad (Clinical and Translational Radiotherapy Research Working Group) – 
providing support for clinical trials. 
 
MetroMRT (Metrology Institutes of Europe, led by the UK National Physical 
Laboratory) - concerned with standardisation of quantitative imaging and 
dosimetry. 
 
The British Nuclear Medicine Society have fostered ongoing communication and 
collaboration between these groups via meetings and teleconferencing and a 
newly formed sub group of the Radiotherapy CRG will focus on MRT. 
6.4 Supply of Radiotherapeutics  
 
The supply of commercial radiotherapeutics is particularly prone to shortages, 
due to the very short shelf life in comparison with chemotherapeutics. For 
example, in the case of the treatment of bone metastases, the chemotherapeutic 
agents Docetaxel and Abiraterone have shelf lives of 36 months and 12 months 
respectively, while the half-lives of 223Ra and 89Sr are 11 days and 55 days 
respectively. Many radiotherapeutic agents may have a shelf life of only several 
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days. It is therefore not possible to stockpile radiotherapeutic agents, even in the 
event of an expected shortage.  
 
With few exceptions, the supply of radiotherapeutics is governed by 
pharmaceutical companies, as the introduction of commercial radiotherapeutics 
into clinical practice increases. This has led to a number of issues that have 
interrupted or prevented patient treatment and associated medical imaging. Two 
examples are given: 
6.4.1 177Lu DOTATATE Treatment of Neuroendocrine Cancer. 
The number of PRRT treatments administered has increased rapidly in recent 
years and growth is forecast to continue significantly as more centres adopt this 
treatment. A potential shortage occurred in 2013 when, following in-house 
production of the 177Lu DOTATATE by hospital radiopharmacies, a patent was 
granted to Mallinckrodt to manufacture and distribute DOTATATE. Exclusive 
rights to develop and commercialise 177Lu DOTATATE were subsequently 
acquired by Advanced Accelerator Applications (AAA). This resulted in a sudden 
threatened shortage of the product and a significant rise in costs. Only a limited 
number of batches were produced each week by the company from a single site 
in Italy. The patent, although potentially an item of dispute, remains in force at 
present, although it is recognized that within Europe, only the UK abides by this.  
6.4.2 223Ra for the Treatment of Bone Metastases (Xofigo) 
This product is currently being evaluated by NICE as a potential alternative to 
abiraterone following docetaxel in CRPC. Xofigo is supplied by Bayer Healthcare 
Pharmaceuticals. All production is based in Norway. There has been a worldwide 
shortage of 223Ra (from early October 2014), imposed at short notice, due to 
contamination of the drug in production, which caused an interruption of 
treatment for a large number of patients, although the lack of a UK registry 
prevents the actual numbers from being known. Some treatments have been 
continued, although the radiobiological consequences of pausing treatment part 
way through a course have not been considered.  
 
The supply of other radiotherapeutics is often not easy to discern although in the 
majority of cases, European supplies are produced in a single manufacturing 
plant. No commercial radiotherapeutic is produced in the UK and in some cases 
there is no production in Europe. For example, the European supply of 90Y resin 
microspheres (Sirtex Medical Ltd), used to treat liver cancer and metastases, 
comes from a site in Singapore, whereas 90Y glass microspheres (BTG plc) are 
exclusively supplied from Canada. 
6.5 Alternative Products 
 
There are potential alternative products for many radiotherapeutic 
radioisotopes in common use, although it should be considered that while there 
is often little or no evidence for the potential benefit of one radioisotope over 
another, there is much conflicting opinion based on clinical judgment and 
experience.  
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To consider the main therapy procedures outlined above: 
131I is obtained from irradiation of tellurium-130 (130Te) in a nuclear reactor. 
While there are at least 2 suppliers of 131I, it is unclear at this stage whether the 
impending closure of reactors will impact on these treatments. 
 
177Lu DOTATATE is obtained from a single supplier (Advanced Accelerator 
Applications) and manufactured in Italy. Alternative radiotherapeutics in routine 
use include 90Y DOTATATE, a product that may be conjugated in a 
radiopharmacy, and variants of ligand, including DOTATOC. 131I  mIBG is also 
used to treat neuroendocrine tumours. 
 
Similarly, the treatment of primary refractory and relapsed paediatric 
neuroblastoma with 177Lu DOTATATE, often treated with 131I mIBG, is currently 
the subject of a clinical trial at UCLH. Unfortunately the vagaries of the NHS 
reimbursement scheme have resulted in at least one further centre not able to 
join the trial. 
 
In addition to 223Ra, metastatic bone deposits have been treated with a range of 
radionuclides, including 89Sr, 153Sm, 186Re, 188Re and 32P. There have been no 
clinical trials to directly compare these products, although large multicentre 
studies to demonstrate increased survival without concomitant chemotherapy 
have only been performed for  223Ra. 
 
90Y microspheres are available from 2 companies. Previously, similar treatments 
have been administered with 131I lipiodol. At least one further product is in 
development, using Holmium-166 (166Ho) in place of 90Y. 
6.6 Projected use of Radiotherapeutics 
 
6.6.1 Novel Therapeutic Radiopharmaceuticals  
A significant number of radiotherapeutics are known to be either in 
development or in early phase clinical trials [4]. Therapeutic radionuclides with 
potential therapeutic benefit but currently unavailable clinically include Astatine 
211 (211At), Copper 67 (67Cu) and Bismuth-212 (212Bi).  The costs of new agents 
to the NHS, and the associated diagnostic scanning required, will be significant 
and will have a large impact on resources. In addition, it can be expected that the 
indication for some radiotherapeutics will be extended. For example, it is feasible 
that bone metastases from other primary cancers, including breast cancer, could 
be treated with 223Ra. 
6.6.2 Costs 
While at this stage projected costs are difficult to estimate, it is certain that an 
exponential rise in the costs of radiotherapeutics is underway as commercial 
products emerge (Figure 6.1). This marks a significant change from traditional 
low cost radiotherapeutics either supplied directly or manufactured in house.  
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Figure 6.1:Previous and predicted costs of radioactive drugs (estimated based 
on previous survey figures and current costs, and projected usage) 
 
As an example of increasing costs, the recent iDUG survey found that a total of 
111 radiotherapeutic treatments were administered for bone metastases from 
prostate cancer [2], at an average cost of ~ £1000 per treatment. It has been 
estimated that with NICE approval of 223Ra, 2000 patients p.a. in the UK will be 
eligible for treatment, which according to the current administration protocol 
will result in 12,000 administrations each year. 223Ra is currently funded through 
the Cancer Drugs Fund at a cost of ~£20,000 for course of six administrations. 
6.6.3 Euratom Directive 
The Euratom directive 2013/59 states that 
‘For all medical exposure of patients for radiotherapeutic purposes <including 
nuclear medicine for therapeutic purposes>, exposures of target volumes shall 
be individually planned and their delivery appropriately verified taking into 
account that doses to non-target volumes and tissues shall be as low as 
reasonably achievable and consistent with the intended radiotherapeutic 
purpose of the exposure.’ 
 
It is further stated that ‘Member States shall bring into force the laws, 
regulations and administrative provisions necessary to comply with this 
Directive by 6 February 2018.’ 
 
Compliance with this directive will entail a dramatic change in the treatment of 
patients with radiopharmaceuticals, as this is now recognised as a form of 
radiotherapy whereby patient-specific dosimetry is mandatory, rather than a 
form of chemotherapy, for which imaging and dosimetry are not possible. 
 
An increasing body of evidence that demonstrates correlations between the 
absorbed doses delivered and response and toxicity underpin the need for 
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dosimetry-based treatment planning, in the absence of such evidence based on 
the administered activities alone [5]. 
6.6.4 Clinical Trials and Research Funding 
As demonstrated by a lack of national or international guidance concerning 
either the levels of activity to administer or the frequency of administration for 
any therapy procedure, there is a paucity of evidence-based clinical trials to 
evaluate the optimal use of any radiotherapeutics currently administered. 
Standardised protocols have been produced only by pharmaceutical companies, 
rather than as a result of academic driven investigations. As examples, Metastron 
(89Sr) is commonly administered with a fixed activity of 150 MBq, whereas both 
Quadramet (153Sm) and Xofigo (223Ra) are administered according to a simple 
weight-based formula (a single administration of 37 MBq/kg and 6 
administrations of 50 kBq/kg respectively). However there are an increasing 
number of clinical trials of therapy radiopharmaceuticals. In addition to the 
ALSYMPCA (223Ra) trial [3] mentioned, commercial clinical trials have been 
conducted for 177Lu DOTATATE [6] and 90Y microspheres [7]. A small number of 
academic trials have been conducted although funding and performing these 
trials has proven difficult and often prohibitive. 
6.6.5 Workforce Issues 
The workforce and resources required to deliver a radiotherapeutic treatment 
safely and effectively are highly specialised. In many cases procedures are more 
resource intensive than is the case for chemotherapeutic drugs due to the need 
for radiation protection, radiopharmaceutical labelling and dispensing, imaging 
and dosimetry. The projected increase in the use of radiotherapeutics for cancer 
treatment, in common with the need for increased capacity to meet the EU 
directive 2013/59 will require a dramatic increase in resources for nuclear 
medicine (Figure 6.2).  
 
 
Figure 6.2 Previous and predicted numbers of radiotherapeutic procedures 
requiring nuclear medicine support 
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Recommendations 
 
 A UK registry for molecular radiotherapy practice is required urgently to 
monitor the use of radiotherapeutics for cancer treatment, particularly as 
new radiotherapeutics are introduced to the clinic. 
 As MRT is a highly multi-disciplinary area, the various stakeholder groups 
should be fully consulted and supported to ensure collaboration 
 The reimbursement scheme for radiotherapeutics should be reviewed to 
enable a clear funding pathway to be identified that will ensure support 
for safe and effective delivery. 
 A full investigation is needed of the supply of radiotherapeutics, as it is 
not possible to stockpile such drugs. Consideration should be given to the 
development of a national radiopharmacy / radiochemistry resource that 
may collaborate with commercial pharmaceutical companies and with 
academic environments as well as with NHS centres to ensure that 
shortages are minimised 
 To ensure optimal and cost effective use of radiotherapeutics, clinical 
trials should be encouraged to determine treatment regimens and to 
compare products that offer a similar treatment.  
 A full cost analysis of the current and projected use of radiotherapeutics 
should be conducted, to include the resource implications for Nuclear 
Medicine and associated disciplines as well as drug costs themselves.  
 An investigation of the impact of the EU Directive 2013/59 should be 
conducted so that this can be met by 2018. 
 A national strategy for the use of radiotherapeutics for cancer treatment 
should be developed to address the supply of radiotherapeutics, projected 
costs of drugs and resources, the clinical introduction of new radioactive 
drugs, national equality of access to treatments and resource planning. 
Consideration should be given to centres of excellence supporting 
satellites. 
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Chapter 7: Nuclear Medicine Workforce 
 
Sarah Allen, Beverley Ellis, Audrey Paterson and Brian Neilly  
Summary 
 
 Accurate information on the size of the nuclear medicine workforce in the 
UK is lacking. This is due to a number of factors including the nomenclature 
used and to diverse ways of recording such data by the professional bodies. 
An initiative is required to bring collect and collate this data for the entire 
UK (not just for NHS England) for future workforce planning.  
 Despite the lack of accurate data, there is good evidence of a workforce 
shortage at all levels of the multi-disciplinary team. This is evident from 
surveys done by professional bodies, difficulties with recruitment, limited 
access to training pathways and from projected retirement of the present 
workforce. 
 The nuclear medicine workforce managed the challenge of past shortages of 
radioisotope but such a response is not sustainable in the long-term. The 
same consideration applies to the wider imaging workforce outside of 
nuclear medicine, especially where alternative imaging studies are involved. 
 Technological innovations in the field of nuclear medicine have driven the 
need for further workforce training but to date initiatives to update and 
make available training programmes are at best patchy. 
 Further initiatives such as 7-day working if applied to nuclear medicine will 
put further pressure on an already stretched workforce and to be effective 
would have to be fully costed and funded. 
7.1 Introduction 
 
The bulk of this report discusses in detail the technical options and 
developments for achieving sustainability of supply of medical radioisotopes 
within and for the UK. However, the technical solutions that can provide 
sustainability of supply in the short, medium and longer term cannot be 
considered in isolation from the workforce who carry out the in-vivo and in-vitro 
radionuclide imaging studies, and treatments using radionuclides. This chapter 
sets out the nuclear medicine workforce considerations and identifies the need 
to ensure that these are addressed.  
 
The term ‘nuclear medicine workforce’ is used throughout this chapter to mean 
the essential core disciplines in the multi-disciplinary team. These include 
clinical practitioners (comprising nuclear medicine technologists and 
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radiographers), clinical scientists, nuclear medicine physicians, nurses, 
radionuclide radiologists, radiochemists, radiopharmacists, and radiopharmacy 
technicians. Other members of the multi-disciplinary team, particularly 
administrative and clerical, and portering staff are also very important. 
 
Additionally, the nuclear medicine specific workforce is drawn from a large 
number of professional groups, including physicians, healthcare scientists, 
healthcare science practitioners, nurses, physicians, radiochemists, 
radiographers, radiologists, and radiopharmacists. Data on sub-specialisation 
such as radionuclide radiology is difficult to access. The difficulty is compounded 
by the use of various professional titles, for example, the terms nuclear medicine 
radiographer, nuclear medicine practitioner, and nuclear medicine technologist 
are all in current use and describe essentially the same job role. It would be 
helpful if the nuclear medicine community would agree and use titles 
consistently, and work with NHS ESR (Electronic Staff Record) [1], to ensure that 
it captures accurately the whole nuclear medicine workforce.  
 
There are particular difficulties in determining the reality of the current 
situation relative to the nuclear medicine workforce. It is small overall carrying 
out approximately 600,000 nuclear medicine, PET or SPECT examinations in the 
UK. This contrasts with 34.5 million imaging tests in England over the period 1 
November 2012 to 31 October 2013 (full year data were not available at the time 
of writing this chapter). However the workforce carry out important and 
complex investigations and therapy using radionuclides. 
 
It is the case that the current nuclear medicine workforce was instrumental in 
maximising the number of studies using 99mTc carried out during the 2008/09 
shortage, and minimising disruption and delay to patients. This was achieved by: 
a combination of extending and altering working hours to fit in with the 
availability of radionuclide activity; modifying (reducing) the administered 
amount of radioactivity in doses used to nevertheless achieve an appropriate 
diagnostic result; and transferring patients for relevant alternative imaging 
modalities that did not rely on 99mTc. 
 
These strategies were sustainable for the short term but, for a longer or long-
term reduction or failure in the supply of 99mTc, it would not be possible for the 
current, already short-handed, nuclear medicine workforce to work extended 
hours, days and weeks indefinitely. Similarly, it might not be easy for non-99mTc 
nuclear medicine, CT and MRI services to absorb the volume of patients referred 
for alternative imaging. 
 
There may also be considerations for the wider imaging workforce outside of 
nuclear medicine, especially where alternative imaging studies such as computed 
tomography (CT) or magnetic resonance imaging (MRI) are used to overcome 
temporary or permanent shortfalls in supplies of medical radioisotopes. 
Implications for the wider workforce are outlined towards the end of this 
chapter. 
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A further complicating factor is the rate of technological innovation; for example 
new radiotracers and nuclear-medicine-based radiotherapeutics is growing fast 
and drawing on an already overstretched workforce. Additionally, if some of the 
novel technologies identified in this report are to become part of the solution to 
the reduced availability of 99mTc, then the current workforce will require 
considerable updating and training in those technologies. 
 
Finally, the recommendations of the future hospital commission include seven 
day care wherever the patients need it, that acutely unwell patients should have 
the same access to medical care on a weekend as on a weekday and that care for 
patients should focus on their recovery enabling them to leave hospital as soon 
as their clinical need allows them to do so [2]. This will have implications for 
how the service including access to nuclear medicine is delivered and will have 
implications for the nuclear medicine workforce. 
7.2 Nuclear Medicine Workforce: The Present Situation 
 
Information and data on the nuclear medicine workforce as a whole is difficult to 
identify as such information has traditionally been gathered by the professional 
or workforce groups, and not all of those who are involved in delivering nuclear 
medicine services will have been part of any relevant workforce survey. 
7.2.1 Clinical Practitioner Workforce 
As discussed above, Clinical Practitioner is the new umbrella term for 
radiographers and technologists working in nuclear medicine. This group forms 
the largest workforce group within nuclear medicine (see Table 2.1 Chapter 2). 
Despite being the largest group, there is acknowledged to be a shortage of 
clinical practitioners in nuclear medicine. A 2011 Society of Radiographers 
survey with responses from 40 Departments in the UK [3] concluded the 
following: 
 Nearly half of the workforce delivering nuclear medicine/radionuclide 
imaging in the responding departments are radiographers. 
 There has been a net increase of 2.1 WTE posts across the 40 responding 
departments in the last two years (less than 1% of the total establishment). 
 The current vacancy rate across all 40 responding departments is 5.0% and 
the 3-month plus vacancy rate is 2.1%. 
 One-fifth of the workforce delivering nuclear medicine/radionuclide 
imaging in the responding departments is due to retire in the next ten years. 
 Around half of the responding departments report an increase in referrals in 
the last two years with around half reporting a decrease, indicating that 
workload appears to have remained steady overall across the responding 
departments. 
 The most prevalent qualifications held by staff delivering nuclear 
medicine/radionuclide imaging are postgraduate diplomas and diplomas of 
radionuclide imaging. 
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There remains a concern about the training of clinical practitioners. The issues 
are summarized in a 2013 editorial in Nuclear Medicine Communications [4]. 
The Modernising Scientific Careers (MSC) initiative to train practitioners by 
commissioning a Practitioner Training Programme for nuclear medicine led to 
the funding of six trainees by the London Local Education and Training Board 
(LETB) but it remains unclear as to the roll out across the UK and the final 
numbers or commitment in the long term. 
7.2.2 Clinical Scientist Workforce 
Accurate data about the numbers Clinical Scientists working in Nuclear Medicine 
is lacking. The Modernising Scientific Careers (MSC) Scientist Training 
Programme (STP) is now established. The first cohort to be trained completed in 
2014 but the impact on the workforce from this programme is unclear. 
Important factors are an increase in the demand and complexity in external 
beam radiotherapy treatments leading to a growing need for clinical scientists to 
work within this area of Medical Physics. Longer-term this could end in 
shortages in the Nuclear Medicine clinical scientists workforce unless training 
numbers are increased. Higher Specialty Scientist Training (HSTT) has started 
but the pathway is not clear for Medical Physics at present.  Recruitment remains 
difficult at high grades as experienced staff members are unlikely to move 
especially to high costs areas. There is limited data on the risk to this workforce 
from budget reductions.   
7.2.3 Medical Workforce 
Consultants: Estimates of the medical workforce in nuclear medicine are 
derived from a number of sources but principally from the Royal College of 
Physicians (RCP) annual census of consultant physicians [5]. Current estimates 
are that there are 75 consultant physicians working in nuclear medicine in the 
UK [5]. However, this underestimates the true medical workforce since reporting 
of nuclear medicine imaging procedures is carried out by clinical radiologists 
with an interest in nuclear medicine imaging. Since radionuclide radiology is a 
subspecialty there is no formal record of the numbers involved with this group. 
Additionally a number of specialists from other disciplines such as cardiology, 
clinical oncology, endocrinology, haematology and neurology hold ARSAC 
certification for a limited number of imaging, non-imaging or therapy serials. The 
true size of the nuclear medicine workforce is therefore difficult to assess 
making workforce planning difficult. 
 
The specialty of nuclear medicine is a consultant-led service. The RCP estimated 
in 2010 that for nuclear medicine the ratio of consultants to population should 
be one whole time equivalent (WTE) per 300,000 population [6]. This figure 
greatly exceeds projections based on current supply and future need based on 
population growth. The 2012 RCP survey revealed that the this figure was 
achieved only in London and the South East and that (subject to the caveat 
mentioned above) the number of WTE Consultant posts per population was well 
below the recommended level and in certain areas of the UK there is no 
dedicated clinical input and the region has relied heavily on the input from 
clinical scientists to maintain the nuclear medicine service in the region [5]. Up 
to one quarter of the identified consultant workforce is expected to reach the age 
of 65 years in the next 10 years.  
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Trainees: Recruitment into the specialty has been a problem in recent years 
with unfilled training posts at specialty training 3 (ST3) level. The origins of this 
are manifold but include uncertainty about future employment and 
preparedness to lead a modern nuclear medicine service given the changes in 
technology (e.g. SPECT-CT, PET-CT, PET-MR) and changes in working practice 
(e.g. integration of the imaging dataset and leadership of the multidisciplinary 
team meetings [MDTs]). In response to this a change to the nuclear medicine 
training programme was proposed and accepted by the General Medical Council 
(GMC) in August 2014 to commence in August 2015. This new nuclear medicine 
training programme will extend the period of training from four to six years, 
provide the trainee with access to the FRCR examination and the Postgraduate 
Diploma in nuclear medicine and allow application for inclusion on to the GMC 
Specialist Register in both nuclear medicine and in clinical radiology. The impact 
of this training is that the new trainees will not complete their training until 
2021. Those presently in training will be offered the opportunity to convert, 
which will extend the period of training. The impact of this is that it will reduce 
the number of available applicants for substantive nuclear medicine consultant 
posts in the short-term.  
7.2.4 Radiopharmacy Workforce 
Radiopharmacy services may be located in pharmacy or nuclear medicine 
departments or may be in stand-alone units. The workforce delivering the 
services is multidisciplinary but broadly divided into scientific and technical 
groupings. Scientific staff may be radiopharmacists, radiochemists or 
radiopharmaceutical scientists and may perform similar roles.  Technical staff 
may be pharmacy technicians, science graduates, radiographers or nuclear 
medicine technologists. All these technical groups may be full-time or rotational 
through radiopharmacy and may perform the same technical roles.  
 
There is a critical shortage of senior-level specialist radiopharmaceutical 
scientists/radiopharmacists to provide professional leadership and to co-
ordinate education and training. There are also shortages of 
radiopharmaceutical technologists and no defined career pathway for this staff 
group. (Centre for Workforce Intelligence–Presentation from WRT’s 2007 multi-
professional imaging review [7]). 
 
A new scientist training scheme (STP) in clinical pharmaceutical science was 
approved and set-up in 2013 under the MSC framework which was a joint 
initiative with modernising pharmacy careers (MPC). This training scheme is for 
pharmacists and scientists and aimed at the pharmaceutical technical specialties 
(which includes radiopharmacy). Although this has been a positive step for long-
term succession planning for scientists/pharmacists it does not address the 
short-term succession planning for senior posts. The current staff undertaking 
this scheme will not be registered until 2017.  
 
There is currently no structured training scheme for radiopharmaceutical 
technologists. Consideration could be given to utilising and training registered 
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pharmacy technicians who are trained in pharmaceutical aseptic services to 
work in radiopharmacy services. 
 
The MPC Board has proposed in a report to Health Education England (HEE) that 
there should be national work force planning for the specialist pharmaceutical 
technical areas. [8].  
 
There may be challenges to collecting the workforce data from the NHS 
electronic staff record (ESR) owing to the different disciplines (pharmacists, 
pharmacy technicians, healthcare scientists and practitioners, radiographers 
etc.) involved in delivering radiopharmacy services and this may not provide 
information on the sub-specialisation of these groups. At present it is not known 
how many of the pharmacy workforce are trained in radiopharmacy.  
 
Consideration needs to be given on how accurate workforce information can be 
obtained for workforce planning, development and commissioning to meet 
future nuclear medicine services 
7.2.5 Workforce Development and Commissioning 
Workforce development solutions are not achieved quickly, with education and 
training taking anything from four to twelve years depending on profession and 
specialism. Traditionally, there has been minimal consideration of the workforce 
as a whole although, in England, the establishment in 2013 of Health Education 
England may help to change this. However, bringing together and coordinating 
postgraduate medical, healthcare science, and clinical practitioner education 
commissioning is likely to prove difficult, and is unlikely to produce tangible, 
positive outcomes in time for the next predicted shortage of 99mTc, predicted for 
2016. 
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Chapter 8: UK Delegation to assess the 
viability of the Canadian schemes for 
cyclotron production of Na99mTc04 
Alan Perkins and Beverley Ellis  
Summary 
 Two production methodologies with the potential to supplement UK 
99mTc supplies on a commercial basis have been identified.  
 The production of 99mTc on high-powered cyclotrons has been 
accomplished with the potential for routine production of TBq amounts of 
radioactivity. 
 99mTc cyclotron production requires high-energy cyclotrons and cannot 
be achieved using the existing medical cyclotron facilities in the UK 
currently used for the production of positron emitting 
radiopharmaceuticals.  
 The key innovation and intellectual property concerning cyclotron 
production of 99mTc rests with the beam targetry and target plate 
technology. 
 Efficient methods for the radiochemical separation and recovery of 
Na99mTcO4 from 100Mo targets have been developed. 
 The radionuclidic purity of cyclotron-produced 99mTc is well understood. 
 Small amounts of 93Tc, 94mTc, 94Tc, 95Tc, and 96Tc impurities may be present 
in variable amounts and with optimisation of cyclotron energy these 
radionuclidic contaminants may contribute an additional 10% in effective 
radiation dose to the patient. 
 Initial work on radiolabelling standard kit formulations has been carried 
out and products have met the current QC specifications.   
 The position relating to the regulatory approval of cyclotron produced 
99mTc radiopharmaceuticals is unclear and further information should be 
sought from both the Canadian regulatory authorities and the MHRA. 
 Economic assessment have shown that cyclotron production of 99mTc 
could be achieved at a cost of <$1Ca/mCi.  
 The radioactive waste implications of routine cyclotron production of 
99mTc have not been quantified.  
 The reliability of routine large-scale production of Na99mTc04 is still to be 
demonstrated. 
8.1 Introduction 
Given that the UK is entirely dependent on the importation of 99Mo for the 
production of 99mTc it was considered necessary to investigate further into the 
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most highly developed methodologies with potential for domestic production. Of 
the various technologies outlined previously in this report, those at a most 
advanced stage with potential for clinical production in the near future have 
been developed at two sites in Canada. A delegation funded by the Foreign and 
Commonwealth Office and the STFC and led by the BNMS visited the Medical 
Isotope Cyclotron Facility (MICF) at the University of Edmonton and TRIUMF in 
Vancouver during October 2014. This fact-finding mission provided first hand 
information on the status of these Canadian 99mTc production technologies.  
8.2 The UK Working Party 
 
Project lead:  Brian Neilly 
Delegation:   Alan Perkins 
Beverley Ellis 
Hywel Owen 
Chris Bee, STFC 
Anthony Gleeson, STFC 
8.3 Cyclotron Technology 
 
The alternative technologies for medical radionuclide production have been 
described in Chapter 4. Canada’s interest in developing alternatives to the 
traditional reactor based technology resulted in two funding initiatives led by 
Natural Resources Canada. In 2010 the Non-reactor-based Isotope Supply 
Contribution Program (NISP) granted $35M for two-year projects. An additional 
$25M was committed for four years from 2012, for the Isotope Technology 
Acceleration Program (ITAP). These funding initiatives have led to two 
promising multi-institutional collaborations. The first is a collaboration between 
the Universities of Edmonton and Sherbrooke and the second is a consortium led 
by TRIUMF. The Alberta and TRIUMF approaches are both based on the 
100Mo(p,2n)99mTc reaction with proton bombardment of an enriched 100Mo 
target (see Figure 8.1). 
 
 
 
Figure 8.1 The p,2n reaction for the production of 99mTc from enriched 100Mo 
 
Initial experiments at both Edmonton and TRIUMF were performed with ACSI 
TR19 cyclotrons, however both centres are going forward with 99mTc production 
based on the TR24 cyclotron. In both cases it is recognized that an incident 
proton energy of at least 19 MeV is required to obtain a good balance between 
radionuclidic purity and product yield. Experimental work carried out to date 
 112 
has demonstrated that there is a dynamic balance between production of 99mTc 
with lower energies offering maximum radionuclidic purity (see Figure 8.2). 
 
 
Figure 8.2 Predicted cyclotron product yields. Taken from A. Celler et. al. [3] 
 
Experiments have shown that cyclotron energies of between 20 and 22MeV 
appear optimum for the production of 99mTc for patient use. Any molybdenum 
cyclotron products (including 100Mo) can be separated out chemically, however 
the other impurities including 93Tc, 94mTc, 94Tc, 95Tc, and 96Tc will remain in the 
final radiopharmaceutical product. These radionuclides will contribute to the 
final patient effective dose following administration. Both Edmonton and 
TRIUMF are working on a worst case scenario/benchmark dose threshold of 
increase in patient dose, which is considered to be of the order of an additional 
10%, this being considered acceptable from a patient protection point of view. 
8.4 Cyclotron Targetry 
 
Given that the feasibility of production by the 100Mo(p,2n)99mTc reaction is well 
established, the reliable production of commercially viable amounts is 
dependent upon innovative targetry, giving due consideration to physical factors 
including melting point, thermal conductivity, thermal expansion, machinability, 
activation properties, mechanical strength, cost, and chemical inertness. Both 
Edmonton and TRIUMF achieve thermal power dissipation by use of an oblique 
target angle and collimation of the beam on a water-cooled target assembly. 
Target stations have been manufactured to allow mechanical or pneumatic 
transport to the hot cells for subsequent dissolution. 
 
The target plates consist of approximately 80 mg of 100Mo that is then sintered 
and pressed into the backing plate (Figure 8.3). Alberta uses an aluminium 
backing plate in a mechanical assembly fitted to the ACSI T24 cyclotron.  TRIUMF 
use a 100Mo target thickness of around 300um on a tungsten backing plate for 
use with both the ACSI TR19/TR24 and GE PET-TRACE cyclotrons.  
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Figure 8.3 Target and backing plate assembly. Left: 100Mo deposited on 
aluminium plates with target assembly in foreground. Right: The underside of 
the target plate showing the entry and exit channels for water-cooling. 
Photographs courtesy of MICF, Edmonton 
 
Enriched 100Mo powder is supplied from Russia and obtained through ISOFLEX 
and URENCO Enrichment Services.  Current stocks are of the order of 25kg, and 
are available at around US $500 per gram. Edmonton are currently considering 
target recycling through a central facility, however TRIUMF are not considering 
this option due to issues of impurities that may affect the administered radiation 
dose to the patient. 
 
From experimental irradiation work a 6-hour bombardment is considered to be 
optimum for routine production. Experimental irradiations on 100Mo targets 
running at 300 μA, 19 MeV, have produced ~340 GBq (TR19), ~174 GBq 
(PETtrace) with recovery of 93% as Na99mTcO4. 
8.4.1 Target Dissolution and 99mTc/100Mo Separation 
(i) University of Alberta (MICF; Medical Isotope and Cyclotron Facility; 
Edmonton) 
The irradiated target was fitted onto the front of the dissolution chamber within 
the hot cell. The target was dissolved in ~30% H2O2, followed by the addition of 
3 M ammonium carbonate.  
 
The dissolved oxidized target solution was transferred under remote control to 
the 99mTc purification and 100Mo recovery system. The extraction process was 
carried out on an automated synthesis unit (e.g. Neptis Mosaic LC) and the 
99mTc/100Mo solution passed through a solid phase extraction resin e.g. ABEC-
2000 column (Aqueous Biphasic Extraction Chromatography) or Tentagel which 
retained the 99mTc pertechnetate while the 100Mo molybdate was eluted. The 
column was washed with 3 M ammonium carbonate to maximise the 100Mo 
recovery. Residual ammonia on the resin was removed by eluting with 1 M 
sodium carbonate.  99mTc pertechnetate was then eluted from the resin using 
distilled water and the solution was neutralised by passing through a cation 
exchange resin before transferring onto an alumina column. The 99mTc 
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pertechnetate was immobilised on the alumina column, which was washed with 
water before eluting the 99mTc with saline into a collection vial [4, 5, 8]. 
 
   
Figure 8.4 Left: System for dissolution of the irradiated target.  
Right: Automated separation synthesis unit.  
Photographs courtesy of MICF, Edmonton. 
 
The dissolution and separation processes (Figure 8.4) were carried out in 
Comecer hot cells (EC GMP Grade C). The final elution of 99mTc pertechnetate was 
terminally filtered using a 0.22 micron filter into the collection vial and this 
process was undertaken in an EC GMP Grade A environment.  
 
(ii) TRIUMF (Vancouver) 
The target dissolution and 99mTc/molybdate separation followed a similar 
process to that described above for the University of Alberta. The target capsule 
was transferred into the hot cell and used directly as a dissolution vessel to 
extract 99mTc from the target plates. The target was dissolved in 30% H2O2 
followed by evaporation of the target solution and dissolution in 4 N NaOH. The 
99mTc pertechnetate purification process was carried out on an automated 
synthesis unit designed for use with disposable kits (e.g. miniAIO; Trasis).  The 
100Mo/99mTc solution in 4 N NaOH was passed through a solid phase extraction 
cartridge containing a resin e.g. ABEC-2000, cross-linked PEG resins and the 
liquid that passed through the resin was collected to recover the molybdenum 
for recycling or reuse. The 99mTc remained trapped on the resin. The resin was 
washed with 4 N NaOH and the 99mTc eluted with water. The eluent was then 
passed through a cation exchange resin (On-guard II H; Dionex) and alumina 
cartridge (Sep-Pak Alumina A; Waters).  After washing the cartridges with water, 
the alumina cartridge was eluted with 0.9% NaCl solution and the 99mTc 
pertechnetate solution was passed through a 0.22 micron filter into the final 
product vial [1, 2]. The approximate time for the dissolution and separation 
processes was 1 hour.  
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8.5 Preparation of 99mTc Radiopharmaceuticals and Quality 
Control 
 
A similar approach was undertaken from both the University of Alberta and 
TRIUMF. Health Canada has agreed that radiolabelling with representative kits 
(neutral, cationic, anionic) and showing that reconstituted kits meet the kit 
manufacturer specifications will be sufficient for approval of cyclotron produced 
99mTc. Kits for neutral (99mTc-exametazime; Ceretec; GE Healthcare), cationic 
(99mTc-tetrofosmin; GE Healthcare; 99mTc-sestamibi; Cardiolite; Lantheus) and 
anionic (99mTc-MDP; Draximage) were reconstituted and tested according to the 
manufacturer’s instructions (including maximum activity levels). 
8.5.1 Radiochemical Purity 
All kits complied with the manufacturer’s limits for radiochemical purity. 
Radiochemical purity was determined using standard thin layer 
chromatography. No significant radiochemical impurities were noted.  
The radiochemical purity of 99mTc pertechnetate was found to be > 95% from 
both centres.   This complies with USP (United States Pharmacopoeia) and Ph. 
Eur (European Pharmacopoeia) and BP (British Pharmacopoeia) limits.   
The expiry time of the 99mTc pertechnetate has not yet been determined but it is 
envisaged that the shelf life of the cyclotron produced 99mTc pertechnetate will 
be 18 or 24 h from production. This work is currently being undertaken. 
The kits have not yet been stressed with maximum activity levels at the end of 
the expiry of cyclotron-produced 99mTc for worst-case scenarios. This work is 
currently being undertaken in the two centres in Canada (November 2014).  
8.5.2 Alumina Content 
The 99mTc pertechnetate was tested for alumina content using a colorimetric test. 
In both centres the alumina content was found to be less than 5 ppm. This 
complies with USP, Ph. Eur and BP limits.   
8.5.3 Radionuclidic Purity 
The radionuclidic purity of cyclotron-produced 99mTc is dependent on the target 
material, irradiation conditions and the time after production at which the 99mTc 
is used (see Chapter 5). The radionuclidic purity was found to be influenced by 
the isotopic composition of 100Mo. This was found to be more important than the 
absolute enrichment level. It was found that 94Mo, 95Mo, 96Mo and 97Mo are 
significant contributors to the production of radionuclide impurities. Both 
groups observed this. The composition of various batches is shown in Table 8.1. 
 
Table 8.1 Isotopic compositions of batches of cyclotron-produced 99mTc [1] 
 
 Isotopic composition (%) 
Batch 92Mo 94Mo 95Mo 96Mo 97Mo 98Mo 100Mo 
99.01 0.09 0.06 0.10 0.11 0.08 0.55 99.01 
97.4 0.005 0.005 0.005 0.005 0.01 2.58 97.39 
99.8 0.003 0.003 0.003 0.003 0.003 0.17 99.815 
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The 100Mo is currently sourced from Isoflex and can be obtained with the desired 
100Mo specification for high quality 99.8% isotopic purity with 94-97Mo content 
below the detection limit. Another potential supplier (URENCO) is being 
investigated. The theoretical dosimetry estimations for radioisotopes produced 
by proton-induced reactions on natural and enriched molybdenum targets [6] 
are discussed in Chapter 5.  
The reported radionuclidic purity from TRIUMF [2] for 99mTc is 99.94% (decay 
corrected to end of beam). Only traces of other technetium radioisotopes (97mTc 
0.003%, 96gTc 0.002%, 95mTc<0.0001%, 95gTc 0.009%, 94mTc 0.044%, 94gTc 
0.012%, 93gTc 0.007%) were detected in the 99mTc pertechnetate.  Other 
radionuclides detected the waste recovery vessel but not the product vial were 
99Mo (0.78%), 96Nb (0.06%) and 97Nb (4.0%). The University of Alberta has 
achieved a radionuclidic purity of 99mTc pertechnetate of 99.98% (at end of 
beam). 
8.5.4 Product Specifications   
There are currently no USP or Ph. Eur monographs for cyclotron produced 99mTc 
pertechnetate but an EP monograph Working Group has been established to 
develop a specification (see Chapter 5). Both centres in Canada are developing 
their own product specifications for cyclotron-produced 99mTc as part of their 
regulatory submission to Health Canada. Tables 8.2, 8.3 and 8.4 outline the 
product specification from the University of Alberta (MICF; Medical Isotope and 
Cyclotron Facility). 
Table 8.2 Specifications (USP [98Mo]; MICF) 
 
Test USP (99Mo from 98Mo) MICF 
Appearance clear, colourless solution clear, colourless solution 
pH 4.5-7.5 4.5-7.5 
Radiochemical Purity >95%  (8/2 acetone/HCl) >95% (acetone) 
Radiochemical 
Identification 
Rf ≈ 0.9 (compare to 
known Tec) 
Rf >0.8 
Radionuclide Identity photopeak @ 140 keV photopeak @ 140 keV 
Aluminium ≤ 10 ppm ≤ 5 ppm 
Residual Solvents n/a <5000 ppm EtOH 
Filter Integrity n/a ≥ 50 psi 
Sterility no growth after 14 days no growth after 14 days 
Endotoxins <175 EU/V <175 EU/V (< 5.8 EU/ml) 
Radionuclidic Purity ≤ 0.015% Mo-99 
≤ 0.05% all other 
see tables below 
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Table 8.3 Radionuclidic/Radioisotopic purity (Pre-release) 
 
Isotopes MICF Lower Detection 
Limit (LDL) (pre-
release) 
TR-19 cyclotron data (End of 
bombardment (EoB) or 18h 
post, worst case) 
99Mo 0.0048% 0.0057% (0.0093%) (18h) 
96Nb 0.0012% < LDL (18h) 
97Nb 0.0006% < LDL (EoB) 
93mTc 0.0027% < LDL (18h) 
93gTc 0.0009% < LDL (18h) 
94mTc 0.0006% < LDL (EoB) 
94Tc 0.0006% 0.0027% (0.0033%) (EoB) 
95Tc 0.0006% 0.0092% (0.012%) (18h) 
96Tc 0.0007% 0.0067% (0.009%) (18 h) 
 
Table 8.4 Radionuclidic/Radioisotopic purity (Post-release) 
 
Isotope MICF LDL Post release TR19 Cyclotron data (18 h 
post EoB) 
99Mo 0.0008% 0.0057% (0.0093%) (18h) 
96Nb 0.0001% <LDL (18h) 
95mTc 0.00007% 0.00011% (0.00014%) 
97mTc 0.014% 0.0475% (0.0618%) 
 
Additional tests undertaken on the final product for chemical purity 
(colorimetric) are:  
1. molybdenum (< 5 micrograms per ml) 
2. peroxide (< 1 microgram per ml) 
 
TRIUMF are also developing a similar specification for cyclotron-produced 99mTc.  
 
The approximate time for dissolution, separation and quality control tests to be 
completed (pre-release) was 2 h (post end of bombardment). At present, there 
has been no large-scale production of 99mTc. It has been calculated that 1.5 TBq 
quantities of 99mTc could be produced after a 6-hour bombardment time (500 
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undertake daily runs of high current large-scale production to demonstrate 
reliability over a 3-month period of continuous production.  
8.6 Waste Products 
 
At the current time the radioactive waste calculations are not complete. The 
long-lived waste products include 99Mo and 95Nb, these having multi-day half-
lives. 
8.7 Regulatory Aspects 
 
Health Canada has two levels of approval and requires an Establishment Licence 
(for New Drug Submission (NDS)) to manufacture, supply and use cyclotron-
produced 99mTc pertechnetate for clinical investigations. These levels of approval 
are for: 
1) Clinical Trials 
2) New Drug Submission (NDS) 
8.7.1 Clinical Trials 
Submission of a Clinical Trial Application (CTA) requires a 30-day review period 
and successful applications are granted an Issue of No Objection Letter (NOL) 
from Health Canada. CTA’s require information (in ICH Common Technical 
Document (CTD) format) such as the clinical protocol, case report form, product 
monograph and a manufacturing file.  
The University of Alberta completed a Phase 1 clinical trial in 2012 for cyclotron-
produced 99mTc using a TR19 cyclotron [7]. A clinical trial with the Centre 
Hospitalier Universitaire de Sherbrooke (CHUS) is being planned for 99mTc 
produced from the TR24 cyclotron [9]. It is not yet known whether the clinical 
trial data obtained from the TR19 will have to be repeated using the TR24. 
TRIUMF are planning to submit a CTA in December 2014 and to initiate a clinical 
trial for cyclotron-produced 99mTc in patients from January 2015.  
8.7.2 New Drug Submission (NDS) 
A NDS requires a 45-day screening and 300-day review process (or 25 day 
screening and 180 day review process if granted priority review) from Health 
Canada. Successful submissions are granted an Issuance of Notice of Compliance 
(NOC) from Health Canada and this confers the ability to market the drug. 
New Drug Submissions require information to be submitted such as product 
overview, supporting clinical/preclinical data, clinical indications, product 
monograph and a manufacturing file. The University of Alberta and TRIUMF both 
anticipate submitting a NDS for cyclotron-produced 99mTc to Health Canada 
during 2015. It is expected that final approval from Health Canada will be 
obtained in late 2016.  
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8.8 Economic Considerations 
 
The business plans for building, commissioning and operation are currently 
under consideration. The costs considered include capital expenditure, 
(cyclotron and radiopharmacy facilities), start-up (training, materials, regulatory 
submissions) variables (salaries, power, consumables, maintenance, etc.), 
administration, insurance, shipping and waste costs. According to the TRIUMF 
team the estimated price is comparable with that of reactor produced 99mTc at < 
Ca $1.00/mCi. 
8.9 Conclusion 
 
Two 99mTc production methodologies using the 100Mo(p,2n)99mTc reaction on 
high powered cyclotrons have been accomplished. The key innovation for the 
implementation of this technology resides with the target plate technology. 
These methods have the potential for routine production of TBq amounts of GMP 
product and could be established in the UK along similar lines to those using 
regional cyclotrons for the production of positron emitting 
radiopharmaceuticals. The technology represents a valuable opportunity for UK 
science and technology, however the reliability of routine production and backup 
arrangements are still to be evaluated. Further commercial investment will be 
requited to develop operational stability and to secure the necessary regulatory 
approvals before this technology is suitable for routine medical use.  
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